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ABSTRACT 
Major depressive disorder is a common severe psychiatric disorder with unknown 
etiology. Recent studies show that the loss and malfunction of oligodendrocytes are 
closely related to the neuropathological changes in depression, which can be reversed by 
antidepressant treatment. St. John’s wort is an effective and safe herbal treatment for 
depression in several clinical trials. However, the underlying mechanism of its 
therapeutic effects is unclear. In this study, we evaluated the effects of hyperforin, a 
major active component of this herb, on the proliferation, mitochondrial function and 
development of oligodendrocytes. We have demonstrated that hyperforin increases 
mitochondrial function and prevents mitochondrial toxin-induced cytotoxicity in 
oligodendrocyte lineage cells. Hyperforin promotes the maturation of oligodendrocytes 
but does not increase the proliferation of oligodendrocyte progenitor cell line and neural 
stem/progenitor cells. Our findings suggest that chronic hyperforin treatment may 
stimulate the development and function of oligodendrocytes. These results suggest a new 
mechanism of hyperforin in depression treatment. Future in vitro and in vivo studies are 
required to further characterize the mechanisms of hyperforin.   
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1 INTRODUCTION 
1.1 Major Depressive Disorder 
1.1.1 Definition and Epidemiology 
Major depressive disorder (MDD), also known as clinical depression, is a very common 
psychiatric disorder. The overall lifetime prevalence of MDD is estimated at 17.1% in the 
United States and 8.6% in Canada (2001; Blazer et al., 1994). Patients with depression 
usually experience fatigue, poor sleep, irritability, feeling of hopelessness and loss of 
interest and pleasure (2000). Depression causes cognitive impairment, psychomotor 
activity retardation and social withdrawal in patients. Severe depression induces suicidal 
ideation, which increases the potential risk of mortality of this disease. The risk of suicide 
for severe MDD patients is estimated to be 15% (Guze and Robins, 1970) and 
approximately 8.6% of hospitalized MDD patients eventually commit suicide (Bostwick 
and Pankratz, 2000). 
1.1.2 Etiology and Pathophysiology 
The etiology of MDD is unknown; however there are genetic, neurobiological and 
psychosocial risk factors. The familial nature of MDD has been observed for many years. 
However, many molecular genetic studies have failed to connect potential gene markers 
to the risk of MDD, because interactions of multiple genes and psychosocial environment 
were quite complicated (Oswald et al., 2004; Reus and Freimer, 1997). Multiple 
psychosocial risk factors can influence the vulnerability to MDD, but the influence of 
environmental stressors from psychosocial factors is also complicated. Over last 50 years 
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many studies have investigated the etiology of MDD, and several neurobiological 
theories have been introduced. 
1.1.2.1 Monoamine Deficiency in MDD 
The monoamine theory dominated neurobiological studies of depression for several 
decades. Clinical observations have found decreased monoamine function in the brains of 
patients with depression, and most antidepressants have been found to enhance serotonin 
and norepinephrine transmission in the brains of patients with MDD (Berton and Nestler, 
2006). Both medication-induced monoamine depletion and dietary restriction of 
tryptophan can produce depressive symptoms in remitted depressed patients (Krishnan 
and Nestler, 2008; Moreno et al., 2000). However, antidepressant treatment need weeks 
to show the mood-enhancing effects in patients with MDD (Berton and Nestler, 2006), 
which suggests that more neurobiological changes go beyond the monoamine deficiency.  
1.1.2.2 Hippocampal Neuron Loss in MDD 
Recent neuroimaging studies have demonstrated that the volume of the hippocampus is 
decreased in brains of patients with MDD (Sheline, 2000). Chronic repeated restraint 
stress, a behavioral model that mimics a depressive-like state in animals, causes atrophy 
and loss of pyramidal neurons in the hippocampus. The atrophy and loss of hippocampal 
neurons are mainly due to lack of neurotrophic support from neurotrophins including the 
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and neurotrophin-
3 (NT-3) (Smith et al., 1995). In a postmortem study, the BDNF expression was reduced 
in the brains of patients with MDD, but it remained unchanged in patients receiving 
antidepressant treatment (Chen et al., 2001b). Chronic stress-induced hypersecretion of 
glucocorticoids also decreases neurogenesis and induces neuronal apoptosis in the 
hippocampus (Joels et al., 2004; Lucassen et al., 2006). 
3 
 
1.1.2.3 Oligodendrocyte Loss in MDD 
Psychiatric disorders such as MDD, schizophrenia and bipolar disorder are associated 
with white matter deficits in postmortem studies (Fields, 2008). White matter is 
composed of neuronal axons wrapped in myelin. Oligodendrocytes, found in the white 
matter, play an important role in information processing by generating myelin which 
regulates the velocity and synchrony of impulse conduction between different cortical 
regions.  
A reduction in white matter reduction has been observed in the prefrontal cortex and the 
limbic system in postmortem studies and structural neuroimaging studies such as 
magnetic resonance imaging (MRI) in patients with MDD (Cotter et al., 2001; Ongur et 
al., 1998). These brain regions are involved in the neural circuits of emotional behavior. 
Oligodendroglial density in the prefrontal cortex of MDD patients is 19% lower than in 
normal controls (Uranova et al., 2004). On the contrary, there is only a decrease in 
neuronal size in the same brain area without a significant decrease in neuronal density 
(Rajkowska et al., 1999). The reduction of the neuronal size is probably due to the loss of 
oligodendrocyte support. One postmortem study has also found that the decreased 
number of glia in the amygdala, an essential area for emotional attention, motivation and 
social behavior (Phelps and LeDoux, 2005), is mainly due to the decreased number of 
oligodendrocytes in the brains of patients with MDD (Hamidi et al., 2004). The decrease 
of myelin basic protein (MBP), a mature oligodendrocyte functional protein, is reported 
in the frontal cortex of MDD patients (Honer et al., 1999). In postmortem studies, 
downregulations of both oligodendrocyte precursor development-related genes and 
oligodendrocyte myelin formation-related genes have been observed in the temporal 
cortex (Aston et al., 2005). The myelin staining of deep white matter in the brains of 
patients with MDD was decreased in the dorsolateral prefrontal cortex which has 
extensive axonal connections to the limbic system and to the cortices (Regenold et al., 
2007; Taylor et al., 2004). In an in vivo study, the toxin-induced glial cell loss alone was 
sufficient to induce depressive-like state in the rat without affecting neurons in prefrontal 
cortex (Banasr and Duman, 2008). Notably, the lifetime risk of MDD for patients with 
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multiple sclerosis (MS), a chronic autoimmune disease with myelin loss in the central 
nervous system (CNS), is around 50% (Arnett et al., 2008) which suggests that the loss of 
oligodendrocytes in CNS may be directly related to the onset of depression. These studies 
suggest that the malfunction and loss of oligodendrocytes in the prefrontal cortex, 
amygdala and limbic system are involved in the neuropathology of major depression. 
Oligodendrocytes can express various neurotrophic factors that influence the survival and 
function of nearby neurons (Du and Dreyfus, 2002). The expressions of BDNF, NT-3 and 
insulin-like growth factor (IGF) in oligodendrocytes have already been indentified in 
animal tissue (Dai et al., 2001). Lower numbers of oligodendrocytes may cause the 
disruption of neurocircuitry and less neurotrophic support for pyramidal neurons in the 
hippocampus (Angelucci et al., 2005). The loss of hippocampal neurons could be a 
consequence of oligodendrocyte loss. 
1.2 Treatment of MDD 
The goal of treatment for MDD is to restore the patients’ normal working abilities and 
social functioning. Different options of treatment are chosen based on the severity of the 
state. Psychotherapy without medicine may be effective for mild to moderate depression. 
Antidepressant treatment is often used for moderate to severe depression. Generally, 50% 
to 70% of patients respond positively to the antidepressant treatment (Schosser and 
Kasper, 2009). Electroconvulsive therapy (ECT) may be used for patients with severe 
depression who have not responded to pharmacotherapy, but the risk of safety and 
amnesia is usually a concern with ECT treatment. In addition to synthetic antidepressants, 
herbal products with antidepressant effects are also widely used for depression. There is 
an increased use of antidepressants by patients with mood disorders (Hsia and Maclennan, 
2009; Raymond et al., 2007), and it is important to explore their mechanisms of action 
and to search for more effective and safer antidepressants. 
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1.2.1 Antidepressants Increase Monoaminergic Neurotransmission 
Most antidepressants affect monoaminergic neurotransmission. Antidepressants exert 
their acute effect mainly by increasing the availability of serotonin, norepinephrine or 
both in the synaptic cleft (Berton and Nestler, 2006). Some antidepressants inhibit the 
presynaptic reuptake transporters of monoamines. Tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake 
inhibitors (SNRIs) are in this category. Others inhibit degradation enzymes of these 
monoamines, for example monoamine oxidase inhibitors (MAOIs) (Charney, 1998; 
Schildkraut, 1995). Most newly developed antidepressants are still based on this acute 
mechanism of action. Although antidepressants immediately increase the monoamine 
levels in the brain, they need to be administered for at least 2-3 weeks to show the mood-
enhancing effects (Pacher and Kecskemeti, 2004). It is now generally believed that other 
mechanisms of action underly the chronic antidepressant treatment.  
1.2.2 Antidepressants Induce Neurogenesis in the Hippocampus 
Currently, the induction of neurogenesis in the hippocampus is considered as one of the 
mechanisms of action for chronic antidepressant treatment. Chronic treatment with 
various antidepressants can upregulate cAMP responsive element binding protein 
(CREB), a transcription factor that activates the genes controlling the expressions of 
BDNF and its receptor, TrkB (Deogracias et al., 2004; Duman, 2002). In an animal study, 
activation of CREB has showed antidepressant effects in the forced swim test (Chen et al., 
2001a). By upregulating the expressions of BDNF and its receptor in the hippocampus, 
antidepressants can induce neurogenesis and prevent neurons from stress-induced atrophy 
and damage (Warner-Schmidt and Duman, 2006). Chronic treatment rather than acute 
treatment with TCAs, SSRIs or MAOIs increases the expression of BDNF in the 
hippocampus of animal models (Duman and Monteggia, 2006).  
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1.2.3 Treatment of MDD and Increased Genesis and Survival of 
Oligodendrocytes 
Although much evidence of pathological changes in oligodendrocytes has been found, 
only a few studies have begun to evaluate the effects of antidepressant treatment on 
oligodendrocytes. Fluoxetine, a widely prescribed SSRI for depression, induces both 
neurogenesis and gliogenesis in the hippocampus and the prefrontal cortex of chronic 
stress rat model (Czeh et al., 2007). Fluoxetine and imipramine, a TCA for depression, 
reverse the loss of neural stem cells in the subventricular zone of a mouse brain after 
chronic stress (Hitoshi et al., 2007), and these surviving neural stem cells may contribute 
to the neurogenesis and gliogenesis in the hippocampus and the prefrontal cortex in this 
mouse. ECT increases the number of mature oligodendrocytes and NG2-positive glial 
cells which are bipotential glial progenitors in the adult rat amygdala (Wennstrom et al., 
2004). ECT also induces cell proliferation in the adult rat prefrontal cortex, and 60% of 
the newly generated cells have been identified as oligodendrocytes or endothelial cells 
(Madsen et al., 2005). Environment enrichment has been found to reduce depressive-like 
behavior in animal model, stimulate proliferation of oligodendrocyte progenitor cells 
(OPCs) and prevent cell death of OPCs in the mouse amygdala (Brenes et al., 2008; 
Okuda et al., 2009). Preventing oligodendrocyte loss and promoting genesis of 
oligodendrocytes are potential mechanisms of action for antidepressant treatment. 
1.3 St. John’s Wort in the Treatment of MDD 
1.3.1 St. John’s Wort as a Medicinal Herb for Psychiatric Disorders  
St. John’s wort (Hypericum perforatum L., SJW) is a well-known medicinal herb widely 
distributed in Europe, West Asia and North Africa. It has been used externally or 
internally to treat respiratory and inflammatory diseases, pectic ulcers and skin wounds 
for 2000 years (Medina et al., 2006). In the 1500s, the Swiss physician Paracelsus first 
used SJW as treatment for psychiatric disorders, such as anxiety, neurosis and depression 
(Bilia et al., 2002). In 1984, the German Federal Health Agency published a monograph 
7 
 
about SJW, recommending its use for depressive moods, anxiety, and nervous unrest. 
SJW is now wildly accepted as an herbal alternative to synthetic antidepressant treatment 
for depression. In Germany, it is prescribed four times more often than commonly used 
synthetic antidepressants. In the United States, it is the second most used medicinal herb 
and is consumed by 17% of Americans (Beaubrun and Gray, 2000).   
1.3.2 Clinical Efficacy of SJW for MDD 
Many randomized and double-blind clinical trials have compared the efficacy and safety 
of standard SJW extracts to placebos and synthetic antidepressants with inconsistent 
results. In 2005, a meta-analysis of 37 randomized controlled trials, including 26 
comparisons with placebo and 14 comparisons with synthetic antidepressants has 
concluded that SJW is more effective than placebos (Linde et al., 2005), and is as 
effective as synthetic antidepressants such as amitriptyline (Wheatley, 1997), fluoxetine 
(Schrader, 2000) and imipramine (Woelk, 2000) in the treatment of mild to moderate 
depression. In 2008, the Cochrane Database Systematic Review of SJW for major 
depression has further suggested that SJW is superior to placebos in patients with MDD 
and is similarly effective as synthetic antidepressants with fewer side effects than 
synthetic antidepressants (Linde et al., 2008). This review was composed of 29 trials 
consisting of 5,489 patients receiving 4 to 12 weeks of treatment, including 18 
comparisons with placebos and 17 comparisons with synthetic standard antidepressants. 
A clinical trial of SJW conducted on behalf of NIH failed to support efficacy in severe 
MDD (2002). However, patients’ plasma levels of hyperforin, a major effective 
component of SJW, were not detectable after treatment with different preparations of 
SJW (Vitiello et al., 2005), and SJW was no different from a proven antidepressant, 
which may suggest a difficult-to-treat population. While the results from the different 
clinical trials are inconsistent, there appears to be evidence from clinical trials to support 
the clinical efficacy of SJW for depression with varying severities. SJW is safe and well-
tolerated compared with synthetic antidepressants, and the side effects of SJW are 
generally mild and transient (Bilia et al., 2002).  
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1.4 Hyperforin as an Antidepressant Extract of SJW 
The most commonly used standard extracts of SJW are hydroalcoholic extracts of the 
aerial portion of the plant (Mennini and Gobbi, 2004). There are several categories of 
compounds in the standard extract of SJW. Phloroglucinols, naphthodianthrones and 
flavonoids are considered to be related to the antidepressant effect of SJW. Hypericin, a 
naphtodianthrone, was initially considered as the major antidepressant component in SJW, 
because it showed inhibitive effect on monoamine oxidase to increase the availability of 
synaptic monoamines (Suzuki et al., 1984). However, a follow-up study reported that 
hypericin was not potent enough to inhibit monoamine oxidase from a dosage of 300 mg 
of SJW three times per day (Bladt and Wagner, 1994). Flavonoids have many 
pharmacological effects, but very few studies have shown that they act as major 
antidepressant components in SJW (Paulke et al., 2008). 
Hyperforin is a phloroglucinol extracted from SJW (Figure 1.1). It accounts for up to 6% 
of the dry weight of SJW extract (Vitiello, 1999). Hyperforin is unstable when exposed to 
light and oxygen, so it was not considered as a candidate component with antidepressant 
effect (Maisenbacher and Kovar, 1992). However, in a randomized, double-blind clinical 
trial of 147 patients, the extract of SJW with 5% hyperforin showed superior efficacy for 
depression compared to 0.5% hyperforin (Laakmann et al., 1998). This study concludes 
that the hyperforin content in the extract is mainly responsible for the antidepressant 
effect of SJW. The dicyclohexylammonium salt of hyperforin has been found to be more 
stable at room temperature with air exposure. Hyperforin.dicyclohexylammonium salt 
(Hyp.DCHA) (Figure 1.1) has been extensively used in in vivo antidepressant studies. In 
several animal studies, Hyp.DCHA has shown antidepressant effects, and the potency is 
correlated to the content of hyperforin (Cervo et al., 2002; Gambarana et al., 2001). 
Hyperforin is now considered the most important compound responsible for the 
antidepressant effect in the SJW extract. 
 (Beerhues, 2006; Dona et al., 2004) 
Figure 1.1 Chemical structures of hyperforin and Hyp.DCHA salt
1.4.1 Pharmacokinetics of Hyperforin as an Antidepressant Compound 
The pharmacokinetic studies of hyperforin in human are only feasible after the 
application of 14C-labelled hyperforin and high-performance liquid chromatography 
tandem mass spectroscopy (HPLC/MS/MS) system which is a highly sensitive and 
selective method to detect hyperforin (Caccia, 2005). In rats, the maximum plasma level 
of hyperforin is approximately 690 nM 3 h after oral administration of 300 mg/kg of SJW 
extract containing 5% hyperforin. In healthy human volunteers, the maximum plasma 
level of hyperforin is approximately 280 nM 3.5 h after one time oral administration of 
300 mg/day of SJW extract containing 5% hyperforin. The estimated steady-state plasma 
concentration of hyperforin after administration of SJW extract (300 mg, three times per 
day) is around 180nM in a repeated dose study (Biber et al., 1998). The inhibitory 
concentration 50 (IC50) of hyperforin as an inhibitor of synaptic uptake of serotonin is 
between 120 nM and 3,300 nM in different in vitro studies (Jensen et al., 2001; Muller et 
al., 1998; Singer et al., 1999). The daily consumption of 900 mg of SJW extract is 
enough to reach the plasma concentration of hyperforin that will inhibit the synaptic 
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reuptake of monoamines. The elimination half-life of hyperforin is 11.2 h in human 
volunteers at the daily dosage of 900 mg of SJW extract (Biber, 1998).The estimated 
brain concentration of hyperforin is only between 30 nM and 60 nM, about 4% of the 
equivalent plasma concentration, in mouse brains after oral administration of SJW extract 
(Keller et al., 2003).  
1.4.2 Mechanisms of Action for Hyperforin as an Antidepressant 
Compound 
Studies have revealed that hyperforin affects the monoaminergic neurotransmission by 
inhibiting synaptic reuptake of monoamines. However, hyperforin exerts this effect 
through a different mechanism compared with synthetic antidepressants. It shows a 
broad-band reuptake inhibition of many neurotransmitters such as serotonin, 
norepinephrine and dopamine at concentrations between 80 nM and 200 nM (Muller et 
al., 1998), and gamma-aminobutyric acid (GABA) and glutamate at concentrations 
between 100 nM and 1000 nM (Wonnemann et al., 2000). Follow-up studies provided a 
possible explanation for this unique mechanism of action for hyperforin. All known 
neurotransmitter transport proteins need to use the sodium gradient as the driving force. 
Hyperforin is able to reduce this sodium gradient by activating Na+- H+ ionic channels 
and increasing sodium uptake into neurons (Muller et al., 2001; Singer et al., 1999). In 
addition, hyperforin can also increase the release of neurotransmitters into the synaptic 
cleft by opening presynaptic calcium channels (Chatterjee et al., 2001). Similar to 
synthetic antidepressants, the antidepressant effect of SJW needs 10 to 14 days of 
treatment to reduce symptoms (Di Carlo et al., 2001).  
1.5 Does Hyperforin Increase Genesis and Survival of 
Oligodendrocytes? 
Most mechanism studies have focused on the effects of hyperforin on monoaminergic 
neurotransmission of neurons. Like synthetic antidepressants, the delayed onset of the 
antidepressant effect with SJW treatment needed to be examined. Although many studies 
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of hyperforin have focused on neurons, there has not been an examination of the effect of 
SJW or hyperforin on neurogenesis in the hippocampus. However, some studies have 
indicated that hyperforin may affect the genesis and survival of oligodendrocytes. 
1.5.1 Does Hyperforin Favor the Genesis of Oligodendrocytes? 
Hyperforin inhibits the interferon gamma (IFNγ) production in activated T lymphocytes 
in an experimental allergic encephalomyelitis (EAE) model, an animal model of MS with 
significant loss of oligodendrocytes (Cabrelle et al., 2008). Treatment targeting the rescue 
of oligodendrocytes and the genesis of oligodendrocytes may alleviate symptoms of MS. 
This study only focused on the protective effect of hyperforin through inhibiting the 
activation of T lymphocytes and cytotoxicity of IFNγ. Several studies have shown that an 
increased number of neural stem cells are generated from the subventricular zone in 
brains of both MS patients and MS mouse models, but the mobilization and 
differentiation of these neural stem cells and the replacement of oligodendrocytes are 
limited (Nait-Oumesmar et al., 2007; Nait-Oumesmar et al., 2008). Whether hyperforin 
can directly induce genesis of oligodendrocytes or promote differentiation and 
remyelination from these newly generated neural stem cells was not examined in this 
study. 
1.5.2 Does Hyperforin Increase Energy Metabolism in 
Oligodendrocytes? 
SJW and hyperforin concordantly regulate expressions of genes related to increasing 
glucose metabolism such as enhancement of glycolysis and cellular glucose uptake in a 
human hepatic cell line (Krusekopf and Roots, 2005). SJW and clomipramine, a TCA for 
depression, both increased protein expressions involved in the cytoskeleton and energy 
metabolism in a proteomic investigation with a mouse hippocampal cell line (Pennington 
et al., 2009). More specifically, SJW increases the expression of pyruvate dehydrogenase 
which is an important enzyme linking carbohydrate substrates from glycolysis to the 
citric acid cycle. 
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Energy consumption of oligodendrocytes is very high during the process of myelination. 
To synthesize and maintain the myelin, oligodendrocytes need to operate at the highest 
metabolic rate of any cell in the brain (Pleasure et al., 1977). Most energy is used for 
acquiring iron to synthesize cholesterol and lipid in myelin and forming mitochondrial 
key enzymes to generate energy by oxidative phosphorylation (Connor and Menzies, 
1996). During the maximal rate of myelination, energy consumption will reach the peak 
in the developing brain (Takahashi et al., 1999). Increased energy demand is considered a 
key factor in the process of differentiation and myelination. Significant malfunction of 
mitochondria and decreased energy metabolism were reported in the brains of patients 
with MDD (Buchsbaum et al., 1986; Drevets et al., 1997; Shao et al., 2008). Decreased 
energy metabolism could cause malfunction or loss of oligodendrocytes in the brains. 
The effect of hyperforin on the survival or differentiation of oligodendrocytes by 
increasing mitochondrial energy metabolism has not studied before.  
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1.6 Hypothesis and Objectives 
The acute mechanism of action for hyperforin as an antidepressant compound is 
increasing monoaminergic neurotransmission. Similar to synthetic antidepressants, this 
acute mechanism of action can not explain the delayed onset of its antidepressant effect. 
The chronic antidepressant effect of hyperforin is more likely mediated by increasing 
oligodendrocyte genesis or function. In this study, we examined the effect of hyperforin 
on the genesis, mitochondrial function and development of oligodendrocytes.  
1.6.1 Hypothesis 
Hyperforin promotes the genesis, mitochondrial function and development of 
oligodendrocytes.  
1.6.2 Objectives 
1. Evaluate the effects of hyperforin on proliferation of CG-4 cells and neural 
stem/progenitor cells (NS/PCs). 
2.  Evaluate the effects of hyperforin on mitochondrial function in differentiating CG-4 
cells and NS/PCs. 
3. Evaluate the effects of hyperforin on development of oligodendrocytes in 
differentiating NS/PCs. 
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2 MATERIALS AND METHODS 
2.1 Cell Culture 
2.1.1 The Central Glia-4 Cell Line 
Central glia-4 (CG-4) cell line is spontaneously generated from the glial cell cultures 
from cerebral cortices of Sprague-Dawley rat (SD rat) pups. The CG-4 cell line used in 
this study is a generous gift from Dr. Adil Nazarali in the College of Pharmacy and 
Nutrition, University of Saskatchewan. This cell line is a bipotential oligodendrocyte-
type 2 astrocyte (O-2A) progenitor cell line (Louis et al., 1992). The O-2A progenitor 
cells are able to differentiate into either oligodendrocytes or type 2-astrocytes in different 
culture media. Several kinds of mitogens, for example the platelet-derived growth factor 
(PDGF) and basic fibroblast growth factor (bFGF), can keep the proliferation of O-2A 
progenitor cells (Stariha and Kim, 2001). When the CG-4 cell line was first established, it 
was cultured in the conditioned medium generated from the culture of neuroblastoma 
B104 cells. Besides mitogens, other ingredients in the conditioned medium may also be 
responsible for keeping the proliferation of the CG-4 cells. 
2.1.1.1 Conditioned Medium of B104 Cell Culture 
B104 is a cell line obtained from a rat neuroblastoma (Schubert et al., 1974). B104 cells 
were maintained in the medium of Dulbecco's Modified Eagle's Medium/Nutrient 
Mixture F12 Ham's (DMEM/F12) (Fisher, SH30023.02) with 10% fetal bovine serum 
(FBS) (Fisher, SH30396.03) (El Bitar et al., 1999). For each T75 flask, B104 cells were 
seeded at the density of 1 x 104 cells/cm2 in 10mL culture medium. Half of the medium 
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was replaced with fresh medium every two days. When the culture was around 60% to 
70% confluent, cells were washed with Hank's Balanced Salt Solution (HBSS) 
(Invitrogen, 14170-112) once and fed with DMEM/F12 and N2 supplement (Invitrogen, 
17520-048). After B104 cells were confluent in DMEM/F12 with N2 supplement for two 
days, this medium became the conditioned medium. The conditioned medium in each 
T75 flask was transferred into a 15 mL centrifuge tube with an addition of 5 µL of 2 
mg/mL Phenylmethylsulfonyl Fluoride (PMSF) in isopropanol to make a final 
concentration of 1 µg/mL PMSF. The conditioned medium was centrifuged at 1000 x g 
for 10 min. The supernatant was filtered with 0.2 µm filter for sterilization and stored at -
80°C for further use.  
The growth medium of CG-4 consisted of 30% of the B104 conditioned medium, 70% of 
DMEM/F12 with N2 supplement, insulin-transferrin-selenium-A (Invitrogen, 51300-044) 
and human transferrin (Invitrogen, 0030124SA) (Table 2.1). The prepared growth 
medium maintained good mitogenic activity in 4°C for a week (McNulty et al., 2001). 
Table 2.1 Recipes of growth medium and differentiation medium for CG-4 cells 
Growth medium Differentiation medium 
DMEM/F12 1:1 DMEM/F12 1:1 
N2 supplement N2 supplement 
Insulin-Transferrin-Selenium-A Insulin-Transferrin-Selenium-A 
human transferrin human transferrin 
B104 condition medium 2% FBS 
 
2.1.1.2 Propagation and Differentiation of CG-4 Cells 
CG-4 cells were grown in Poly-D-Lysine (Chemicon, A-003-E) coated 100mm tissue 
culture dishes with growth medium. The initial density of cells recovered from 
cryopreservation was 2 x 103 cells/cm2 in growth medium. Half of the growth medium 
was replaced every two days, and cells were passaged every three days. To passage CG-4 
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cells, cells were washed with 4 mL of harvesting medium consisting of 50% of HBSS, 
50% of Versene (Invitrogen, 15040-066) with Insulin-Transferrin-Selenium-A. Cells 
were triturated 20 times, so they would detach from the surfaces of tissue culture dishes. 
The cell suspension was transferred into a 15 mL centrifuge tube and centrifuged at 120 x 
g for 5 min. After the supernatant was discarded, cells were resuspended in 4mL of 
growth medium. The cell number was counted in a hemocytometer with 1% of trypan 
blue solution. Cells were seeded at a density of 1 x 103cells/cm2 in a 100 mm tissue 
culture dish with 10 mL of growth medium. Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2/95% air. 
The differentiation of CG-4 cells was initiated by withdrawing the B104 conditioned 
medium and substituting it with 2% of FBS (Table 2.1). CG-4 cells mainly differentiated 
into oligodendrocyte lineage cells in the presence of a low concentration of FBS (2%) 
without any mitogen in the medium (Louis et al., 1992). CG-4 cells began to show 
morphological characteristics of mature oligodendrocytes within two days when 
maintained in the differentiation medium (Stariha and Kim, 2001). 
2.1.1.3 Cryopreservation and Recovery of CG-4 Cells 
Half of growth medium was replaced one day before cryopreservation. When cells were 
around 80% confluent, cells were harvested and counted with 1% of trypan blue solution. 
Cells were cryopreserved at the concentration of 2 x 104 cells/mL in freezing medium, 
containing growth medium with 8% of dimethyl sulfoxide (DMSO). Cell suspension was 
transferred into labeled 1.5 mL cryovials. Cryovials were put in the controlled-rate 
freezing jar containing isopropyl alcohol. Cryovials were left in the jar at -80°C for 24 h 
and then transferred into a liquid nitrogen tank for long-term storage. 
Cryovials containing CG-4 cells from a liquid nitrogen tank were quickly transferred into 
a 37°C water bath and swirled for 2 min to facilitate the thawing. Cell suspension was 
transferred into a 15 mL centrifuge tube containing 8mL of prewarmed growth medium. 
After gently being triturated 5 times, cell suspension was centrifuged at 120 x g for 5 min. 
The supernatant was discarded. Cells were resuspended at the density of 2 x 102 cells/cm2 
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in a 100 mm tissue culture dish with 10 mL of growth medium. Cells were incubated at 
37°C in a humidified atmosphere of 5% CO2/95% air. 
2.1.2 Neural Stem Cells and Neural Progenitor Cells 
Neural stem cells are undifferentiated cells that maintain the ability to proliferate and self 
renew. Neural stem cells can be isolated from embryonic and adult brains (Temple and 
Alvarez-Buylla, 1999). Neural stem cells are multipotent and able to differentiate into 
three types of functional cells: neurons, astrocytes, and oligodendrocytes. Four conditions 
are required for the neural stem cell culture: low cell density, an absence of serum, 
addition of the growth factors, such as epidermal growth factor (EGF) and/or bFGF, and 
an absence of a strong cell adhesion substrate (Gritti et al., 1999; Reynolds et al., 1992). 
Under these culture conditions, neural stem cells proliferate and aggregate into floating 
neurospheres. Neurospheres are a heterogeneous clonal group of cells expressing the 
neuroepithelial protein nestin, which is considered a marker of NS/PCs. Only a 
proportion of cells within a neurosphere are neural stem cells, while the other cells are 
neural progenitor cells. Due to lack of specific markers for neural stem cell, NS/PCs are 
used to refer to the cell population identified by nestin in the neurosphere culture 
(Gilyarov, 2008). 
2.1.2.1 Collection of Embryonic Brain Tissue 
Sterilized ice-cold HBSS containing 50 µg/mL gentamicin was prepared in several 100 
mm and 35 mm tissue culture dishes for the process of dissection. At gestation day 16, 
the pregnant SD rat was anesthetized with isoflurane in an air-tight container. The 
pregnant SD rat was sacrificed by cervical dislocation after being anesthetized. The 
pregnant rat was laid on the paper towels and sprayed with 70% ethanol. The abdominal 
area was thoroughly rinsed with 70% ethanol. The skin above the genitalia was cut with 
large scissors to open the peritoneal cavity. The uterus was removed with sterilized 
scissors and forceps and then put into the first 100 mm dish with ice-cold HBSS. 
18 
 
Embryos were removed from the uterus and transferred into the second 100 mm dish with 
ice-cold HBSS using a small scissor.  
Heads of embryos were cut off just below the cervical region. The head was held with 
fine curved forceps from the caudal sides at the ears to position the head side up. The 
skull was cut and opened with microscissors. After the skull was opened, the brain was 
squeezed out of the skull by pushing on the front of the head. All brains were transferred 
into the third 100 mm dish with ice-cold HBSS and put under a dissecting microscope 
(10X magnification) for dissection. The meninges were teased off with microforceps. The 
cortices were dissected for primary culture. The dissection was completed in 2 h, before 
the brain tissue became soft and sticky.  
2.1.2.2 Primary Culture of NS/PCs from the Cortex 
The cortices were cut into small pieces with microscissors and then transferred into a 15 
mL centrifuge tube. To digest the cortices, 5 mL of accutase (Sigma, A6964) was added 
into the tube. The cortices were digested at 37°C with often pipetting to make a cloudy 
cell suspension. The cell suspension was passed through a 40 µm sterile mesh to get the 
single cell suspension. The single cell suspension was centrifuged at 120 g for 5 min. 
After the supernatant was discarded, cells were resuspended in 5 mL of growth medium 
containing DMEM/F12, B27 supplement (Invitrogen, 17504), 20 ng/mL bFGF 
(Chemicon, GF003) and 20 ng/mL EGF (Chemicon, 01-107) (Table 2.2). Cells were 
seeded at a density of 5 x 104 cells/cm2 in a T-75 flask with 12 mL of growth medium. 
Cells were incubated at 37°C in a humidified atmosphere of 5% CO2/95% air. Half of the 
medium was replaced every two days. The NS/PCs proliferated quickly to form 
neurospheres. After 5 days of proliferation in the growth medium, the average diameter 
of the neurospheres reached approximately 100 µm. From this point, the primary 
neurospheres were either used for characterization and experiments or passaged to avoid 
the differentiation and death of the cells inside the neurospheres due to the lack of supply 
of growth factors or nutrition. 
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2.1.2.3 Characterization and Differentiation of NS/PCs 
When the neurospheres were ready to be passaged, floating neurospheres were 
transferred into a well of a 24-well tissue culture plate with 670 µL of growth medium. 
Neurospheres attached to Poly-D-Lysine coated sterile 20 mm diameter coverslips in the 
wells of a 24-well tissue culture plate after 4 h. Immunocytochemical staining was used 
to detect the expression of the nestin in the neurospheres. The rabbit polyclonal to nestin 
(Abcam, ab5968) was used at a dilution of 1: 200 for the staining. Most cells were found 
nestin-positive in the neurospheres.  
The spontaneous differentiation of NS/PCs was initiated by withdrawing the EGF and 
bFGF from the basal medium and substituting it with 2% of FBS (Table 2.2). The Poly-
D-Lysine coated surface favored the differentiation of the NS/PCs. After 72 h of 
differentiation in the differentiation medium, different biological markers were chosen to 
identify premature neurons, astrocytes and oligodendrocytes in the culture using 
immunocytochemical staining. NS/PCs in the neurospheres could differentiate into 
premature neurons, astrocytes and oligodendrocytes.  
Table 2.2 Recipes of growth medium and differentiation medium for NS/PCs 
Growth medium Differentiation medium 
DMEM/F12 1:1 DMEM/F12 1:1 
B27 supplement B27 supplement 
20ng/mL EGF and 20ng/mL bFGF  2% FBS 
 
2.1.2.4 Propagation and Cryopreservation of NS/PCs 
NS/PCs were expanded to create stocks of cells for further experiments. The primary 
culture was named passage 0 and following passages were named passage 1 and 2, etc. 
Only passage 1 and passage 2 were used in this study. Neurospheres were transferred into 
a 15 mL centrifuge tube. Neurospheres would sink to the bottom of the tube in 10 min. 
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The supernatant was removed by suction. At this point, NS/PCs were either 
cryopreserved or propagated. To cryopreserve NS/PCs, neurospheres were maintained in 
growth medium containing 10% DMSO. Neurospheres were transferred into 1.5mL 
cryovials and put in the controlled-rate freezing jar. Cryovials were left in the jar at -80°C 
for 24h and then transferred into liquid nitrogen for long-term storage. To propagate 
NS/PCs, accutase was added to digest the neurospheres into single cell suspension. The 
neurospheres were digested at 37°C with often pipetting to make a cloudy cell suspension. 
Single cell suspension was centrifuged at 120 x g for 5 min. After the supernatant was 
discarded, cells were resuspended in 5 mL of growth medium. Cells were seeded at a 
density of 2 x 104 cells/cm2 in a T-75 flask with 12 mL of growth medium. Cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2/95% air. Half of the growth 
medium was replaced every two days. Floating single cells would grow into neurospheres 
of NS/PCs in 5 days.  
2.2 Preparation of Hyperforin 
In this study, the hyperforin.dicyclohexylammonium salt was used instead of pure 
hyperforin. To prepare a stock solution at the concentration of 7 mM/mL, 1 mg of 
hyperforin.dicyclohexylammonium salt (Alexis, ALX-350-097-M001) was dissolved in 
200 µL of DMSO. Each aliquot of 10 µL stock solution in a 1.5 mL sterile tube was 
stored at -80°C avoiding light for long-term storage. Different concentrations of 
hyperforin were freshly prepared by diluting the stock solution with sterile double 
distilled water (ddH2O). The concentrations of hyperforin in different assays are chosen 
based on preliminary studies and literature from similar studies. The dosage range usually 
is wide enough to show different effects of hyperforin at different concentrations in each 
assay. The concentrations of DMSO used in dilutions never exceeded 0.05%. The 
preliminary study has shown that DMSO at these concentrations as a vehicle does not 
significantly affect all the parameters in this study compared with the control of culture 
media. There is a comparable amount of DMSO in each 0.0 µM group with other 
treatment groups, and the DMSO does not significantly affect the parameter in each assay. 
21 
 
2.2.1 Treatment of CG-4 Cells with Hyperforin 
In growth medium, 0.0 µM, 0.01 µM, 0.05 µM, 0.1 µM, 0.5 µM and 1.0 µM of 
hyperforin treatment were used to study proliferation. In differentiation medium, 0.0 µM, 
0.0625 µM, 0.125 µM, 0.25 µM, 0.5 µM and 1.0 µM of hyperforin treatment were used 
in MTT assay, ATP assay and Rhodamine123 assay. In WST-8 assay, 0.0 µM, 0.125 µM, 
0.5 µM, 1.0 µM of hyperforin were used. In BrdU incorporation assay, 0.0 µM, 0.1 µM, 
0.5 µM, 1.0 µM of hyperforin were used. 
2.2.2 Treatment of NS/PCs with Hyperforin 
In growth medium, 0.0 µM, 0.15625 µM, 0.3125 µM, 0.625 µM, 1.25 µM and 2.5 µM of 
hyperforin treatment were used in a 24 h proliferation study and 0.0 µM, 0.05 µM, 0.1 
µM, 0.5 µM, 1.0 µM and 2.5 µM of hyperforin treatment were used in a 48 h 
proliferation study. In differentiation medium, 0.0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5.0 
µM and 10 µM of hyperforin were used to study mitochondrial function and 0.0 µM, 
0.15625 µM, 0.3125 µM, 0.625 µM, 1.25 µM and 2.5 µM of hyperforin treatment were 
used to study development of oligodendrocytes. 
 
2.3 Experimental Design 
2.3.1 Effect of Hyperforin on Proliferation in CG-4 Cells and NS/PCs 
 
 
2.3.2 Effect of Hyperforin on Mitochondrial Function in CG4 Cells and 
NS/PCs 
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2.3.3 Effect of Hyperforin on Rotenone-induced ATP Depletion  
 
2.3.4 Effect of Hyperforin on the Development of Oligodendrocytes in 
Differentiating NS/PCs  
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2.4 Tetrazolium Microplate Assays 
2.4.1 MTT Assay 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) powder was 
purchased from Invitrogen (M-6494). To make 5 mg/mL MTT stock solution, 1 g of 
MTT was dissolved in 200 mL of sterile 0.1 M phosphate buffered saline (PBS). The 
solution was passed through the 0.2 µm filter. The aliquots were stored in 1.5 mL sterile 
eppendorf tubes. The stock solution was put into a paper sample box avoiding exposing 
to light in a -20°C freezer for long-term storage. The stock solution was thawed and 
added into the cell culture of a 96-well plate to achieve a working concentration of 
0.5mg/mL. The cells were incubated with MTT at 37°C in a humidified atmosphere of 
5% CO2/95% air for 4 h. After the incubation, the culture medium was removed. To 
dissolve the formazan, 100 µL of DMSO was added into each well to get the purple 
solution. The 96-well tissue culture plate was gently shaken for 1 min to make sure all the 
formazans were dissolved before the measurement. The absorbance of the purple solution 
in each well was measured with a microplate reader (PerkinElmer, VICTOR3 Multilabel 
Plate Reader) at the wavelength of 550 nm. Triple blank controls were included in each 
experiment setup. The blank controls contained cultured cells with the same treatment as 
others but without the addition of MTT. To get the real optical density value for each 
well, the average value of blank controls was subtracted from the direct readout value. 
2.4.2 WST-8 Assay 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H tetrazolium, 
monosodium salt (WST-8) 10X stock solution was purchased from Dojindo (CK04-11). 
After the cell cultures were treated with hyperforin and vehicle for 24 h and 48 h, 10 µL 
of WST-8 stock solution was added into each well of a 96-well tissue culture plate. The 
cells were incubated with WST-8 at 37°C in a humidified atmosphere of 5% CO2/95% air 
for 4 h. After the incubation, the absorbance of the soluble formazan in each well was 
measured with a microplate reader at the wavelength of 450 nm. Triple blank controls 
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were included in each experiment setup. The blank controls contained cultured cells with 
the same treatment as others but without the addition of WST-8. To get the real optical 
density value for each well, the average value of blank controls was subtracted from the 
direct readout value. 
2.5 BrdU Incorporation Assay 
5-bromo-2-deoxyuridine (BrdU) is a synthetic analogue of thymidine, which can 
incorporate into newly replicating DNA during the S phase of the cell cycle. BrdU can be 
detected by immunocytochemistry using a monoclonal antibody against the single-
stranded DNA containing BrdU (Gratzner, 1982). BrdU incorporation assay is as 
sensitive as [3H]-thymidine incorporation assay to study cell proliferation. It is a faster 
cell proliferation assay without handling radioactive isotopes (Taupin, 2007).  The BrdU 
incorporation assay was used to measure the DNA synthesis in CG-4 cell culture in this 
study. 
The colorimetric cell proliferation enzyme linked immunosorbent assay (ELISA), BrdU 
assay kit (11647229001) was purchased from Roche Applied Science. Cells were 
cultured in 96-well tissue culture plates at the density of 5 x 103 cells/cm2 with different 
concentrations of hyperforin treatment. After treating the cells with hyperforin or vehicle 
for 24 h or 48 h, 10 µL of BrdU labeling solution was added to each well to get a working 
concentration of 10 µM of BrdU. After 3 h of incubation, the BrdU labeling solution was 
removed by pipetting. To fix the cells and denature the DNA, 200 µL of FixDenat was 
added to the cell culture to improve the detection of BrdU by the antibody. The FixDenat 
solution was removed by pipetting after 30 min of incubation in a 25°C incubator. To 
bind to the incorporated BrdU in newly synthesized DNA, 100 µL of anti-BrdU-POD 
solution was added to wells. Anti-BrdU-POD solution was removed by pipetting after 90 
min of incubation in a 25°C incubator. To wash wells, 250 µL of 0.01 M PBS was added 
for rinsing three times. After washing, 100 µL of substrate solution was added to initiate 
the reaction at 25°C. For the first time experiment, the reaction was not stopped, so the 
optical density of reaction product was measured at the wavelength of 370 nm at the 
different time points of 5 min, 10 min and 20 min to determine the optimal reaction time. 
After the pilot experiment, 10 min of reaction was determined as the optimal reaction 
time in this study. To stop the reaction at the time point of 10 min, 25 µL of 1 M 
sulphuric acid (H2SO4) was added to each well, and the solution was shaken for 
approximately 1 min to mix thoroughly. The optical density of reaction product in each 
well was measured at the wavelength of 450 nm after the addition of the stopping reagent. 
Triple blank controls were included in each experiment setup. The blank controls 
contained 100 µL of culture medium, 10 µL of BrdU labeling solution and 10 µL of anti-
BrdU-POD solution. The blank control provided information about the unspecific 
binding of BrdU and anti-BrdU-POD conjugate to the tissue culture plate. To get the real 
optical density value for each well, the average value of blank controls was subtracted 
from the direct readout value. 
2.6 ATP Assay 
Firefly luciferase is widely used to measure the adenosine triphosphate (ATP) levels in 
isolated mitochondria and permeabilized cells. During the luciferase catalyzed reaction of 
luciferin, ATP and oxygen to the oxyluciferin, the maximum yellow-green 
bioluminescence emits at 560 nm at pH 7.75 (McElroy and DeLuca, 1983). ATP assay is 
based on the quantitative analyses of the linear relation between the bioluminescence and 
ATP concentrations (Mueller et al., 2004). It is a very sensitive assay and capable of 
measuring 1 x10-11 to 1 x10-16 moles of ATP. 
Luciferase + Luciferin + ATP             Luciferase - Luciferyl - AMP + PPi 
Luciferase - Luciferyl - AMP + O2            Luciferase + Oxyluciferin + AMP + CO2 + hν  
(Deluca, 1976) 
2.6.1 Sample Preparation 
CG-4 cells were cultured in Poly-D-Lysine coated 24-well tissue culture plates at the 
density of 5 x103 cells/cm2 with 670 µL of differentiation medium. The cells were treated 
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with different concentrations of hyperforin for 24 h and 48 h, or the combination of 
hyperforin and rotenone for 24 h. 
2.6.2 ATP Extraction 
Trichloroacetic acid was used to disrupt cell membranes and release adenine nucleotides 
in the ATP-extracting medium. Trichloroacetic acid also prevented ATP from 
degradation by ATP eliminator enzymes. Trichloroacetic acid is recognized as the most 
effective extractant, because the levels of ATP extracted by trichloroacetic acid most 
closely reflect the actual levels of ATP in cells (Lundin and Thore, 1975). Ethylene 
diamine tetraacetic acid (EDTA) was also included in the extracting medium to 
irreversibly inactivate ATP-converting enzymes by chelating the Mg2+. The ATP-
extracting medium contained 10% of trichloroacetic acid and 2 mM EDTA (Stanley, 
1986). The culture medium was removed from each well of a 24-well plate by pipetting. 
To extract ATP from cells, 500 µL of ice-cold ATP-extracting medium was added in 
each well and the plate was put on ice for 30 min. The plate was gently shaken several 
times during the extraction. After extraction, 40 µL of extracting medium from each well 
of a 24-well plate was transferred into a well of a 96-well plate. Triple wells were used 
for the extraction from each treatment group to ensure the accuracy of measurement. 
2.6.3 Sample Dilution 
Trichloroacetic acid strongly inhibited the firefly luciferase reaction, so the 
trichloroacetic acid in the extracted samples were diluted to a final concentration of less 
than 0.1% before the bioluminescent ATP assay was begun (Nichols et al., 1981). The 
trichloroacetic acid in extracting medium was 1: 40 diluted to a final concentration of 
0.05% by 1: 5 diluted and then 1: 8 diluted with ice-cold sterile 0.1 M Tris-acetate buffer, 
2 mM EDTA at pH 7.75. The diluted sample was placed on ice for assay. 
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2.6.4 Performing ATP Assay 
The ATP Determination Kit was purchased from Invitrogen (A22066). To make 1 mL of 
the 10 mM D-luciferin stock solution, 1 mL of 1X Reaction Buffer was added to the vial 
of D-luciferin prepared by the kit on the day of the assay. For long-term storage, 1.62 mL 
of 100 mM Dithiothreitol (DTT) stock solution was prepared by sterile ddH2O and 
aliquoted 150 µL of solution into each 1.5 mL eppendorf tube, and 30 µL of 5 mM ATP 
stock solution was aliquoted into each 1.5 mL eppendorf tube. For long-term storage, 3 
µL of 5 mg/mL luciferase, firefly recombinant enzyme solution was aliquoted into each 
1.5 mL eppendorf tube. All the stock solutions were stored at –20°C and protected from 
light for further use in several weeks. 
On the day of the assay, all the components were combined to make 10 mL of standard 
reaction solution using the following recipe: 
Sterile ddH2O      8.9 mL 
20X Reaction Buffer     0.5 mL 
0.1 M DTT       0.1 mL 
10 mM D-luciferin    0.5 mL   
Firefly luciferase 5 mg/mL stock solution 2.5 μL 
The solution was gently mixed to avoid denaturing the firefly luciferase. The standard 
reaction solution was made right before it was added to the samples to prevent the 
activity of firefly luciferase decreasing with time at room temperature. To make 1 µM of 
ATP stock solution, 20 µL of 5 mM ATP stock solution was diluted at 1:5000 in 10 mL 
of sterile 0.1 M Tris-acetate buffer, 2 mM EDTA, pH 7.75. The following concentrations 
were used to make the standard curve: 1000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 
31.25 nM and 0 nM. The measurement of the ATP standard curve was included in each 
microplate experiment setup. For assay, 10 µL of each standard ATP solution or sample 
was added to a well of a sterile nontransparent white sterile microplate (Fisher, 14-245-
182). Standard ATP solutions were added to the microplate by using double wells. 
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Samples were added to the microplate by using triple wells. The reaction was initiated by 
adding 100 µL of standard reaction solution to each well with gentle shaking. The 
microplate was put at room temperature for 4 min before the bioluminescence was read to 
make sure the reaction was stable. The bioluminescence was read in a microplate reader. 
The amount of ATP in each experimental sample was calculated from the standard curve. 
2.7 Rhodamine123 Assay 
The measurement of mitochondrial membrane potential usually uses noninvasive 
lipophilic dyes with positive charges. They are actively transported into the mitochondria 
but they can not freely pass through the membrane (Haydon and Hladky, 1972). They 
accumulate in mitochondria proportionally to the mitochondrial membrane potential. The 
first and most widely used dye to measure mitochondrial membrane potential is 
Rhodamine123 (Chen et al., 1982).  
Rhodamine123 was purchased from Sigma (R8004). To make a 50 mM stock solution, 
25 mg of Rhodamine123 was dissolved in 1.31 mL of DMSO. The stock solution was 
stored at –20°C and protected from light for long-term storage. CG-4 cells were cultured 
in Poly-D-Lysine coated 24-well tissue culture plates at the density of 5 x 103 cells/cm2 
with 670 µL of differentiation medium. The cells were treated with different 
concentrations of hyperforin for 24 h and 48 h. Before use, Rhodamine123 stock solution 
was diluted in culture medium to get a 25X stock solution at 50 μM. Rhodamine123 was 
added to cell culture at a final concentration of 2 μM with gentle shaking. Cells were 
incubated with Rhodamine123 for 30 min at 37°C. After incubation, cells were washed 
with cold HBSS three times. After being washed, cells were lysed with 500 μL of radio 
immunoprecipitation assay (RIPA) solution in each well of a 24-well plate. The cell 
lysate of each well was transferred into a well of a nontransparent black 96-well plate 
(Fisher, 09-003-34). Samples from each group were added to the microplate by using 
triple wells. Fluorescence was read at 480 nm for excitation and 530 nm for emission 
with a microplate reader. Triple blank controls were included in each experiment setup. 
The blank controls contained 100 µL of culture medium and 2 μM of Rhodamine123. 
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The blank control provides information about the unspecific binding of Rhodamine123 to 
the tissue culture plate. To get the real optical density value for each well, the average 
value of blank controls was subtracted from the direct readout value.  
2.8 Immunocytochemical Staining 
2.8.1 Plating Cells and Incubation 
For characterization of NS/PCs, neurospheres were seeded in a 24-well tissue culture 
plate with Poly-D-Lysine coated coverslips at the density of 5 x 102 spheres/cm2 in 
growth medium. Neurospheres were incubated at 37°C in a humidified atmosphere of 5% 
CO2/95% air for 4 h to allow attachment to the coverslips. For differentiation assay of 
NS/PCs, NS/PC single cell suspension was seeded in a 24-well tissue culture plate with 
coverslips at the density of 5 x 104 cells/cm2 in growth medium. NS/PCs were incubated 
at 37°C in a humidified atmosphere of 5% CO2/95% air for 16 h to allow attachment to 
the coverslips. After cells attached to the coverslips, the growth medium was replaced by 
differentiation medium. NS/PCs began to differentiate into neurons, astrocytes and 
oligodendrocytes in the differentiation medium. Cells were treated with different doses of 
hyperforin from 0.0 μM to 2.5 μM for up to 96h.  
2.8.2 Fixation and Blocking 
The culture medium was removed and cells were gently rinsed with 0.01 M PBS once. 
500 µL of freshly made 4% paraformaldehyde (PFA) were added to each well to fix cells 
for 15 min at room temperature. After the 4% PFA was removed, the fixed cells were 
washed with 600 µL of 0.01 M PBS for three times with gentle shaking, 10 min for each 
time. The fixed cells were blocked with 500 µL of blocking solution containing 5% of 
appropriate sera in 0.01 M PBS with 0.3% of Triton X-100 at room temperature for 1 h 
with gentle shaking. The sera for blocking should be from the same type of animal as the 
animal of the secondary antibody.   
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2.8.3 Antibody Incubation 
After blocking, 400 µL of primary antibody solution diluted at the proper concentration 
in blocking solution was added to each well except the well of the blank control. Cells 
incubated with primary antibodies were put into a 4°C fridge over night. For 
characterization of NS/PCs, rabbit anti-nestin (Abcam, ab5968) at the dilution of 1: 400 
was used to stain NS/PCs. Mouse anti-2', 3’-cyclic nucleotide 3' phosphodiesterase 
(CNPase) (Millipore, MAB326) at the dilution of 1: 200 and goat anti-MBP (Santa Cruz, 
sc-13914) at the dilution of 1: 400 were used to stain oligodendrocytes. Mouse anti-Glial 
fibrillary acidic protein (GFAP) (Millipore, MAB3402) at the dilution of 1: 1000 was 
used to stain astrocytes. Mouse anti- β-III tubulin (Millipore, MAB1637) at the dilution 
of 1: 400 was used to stain neurons. After the incubation with primary antibody, 
uncoupled primary antibody was washed away by 0.01 M PBS for three times with gentle 
shaking, 15 min for each time. Blocking solution (400 µL) with proper fluorescent 
secondary antibody at the concentration of 2 µg/mL was added to each well. Plates were 
covered with aluminum foil to protect the fluorescent secondary antibodies from light. 
Cells with secondary antibodies were incubated at room temperature for 1 h with gentle 
shaking.  
2.8.4 Hoechst 33342 Staining 
After the incubation with secondary antibodies, cells were incubated with 400 µL of 1 
mg/mL Hoechst 33342 in 0.01 M PBS for 5 min at room temperature to stain the nuclei 
DNA. Plates were covered with aluminum foil to protect fluorescent Hoechst 33342 from 
light. Uncoupled secondary antibodies and Hoechst 33342 were washed away with 600 
µL of 0.01 M PBS for three times with gentle shaking, 15 min for each time.  
2.8.5 Mounting 
The PBS used for washing was removed thoroughly before mounting. A drop of 
fluoromount aqueous mounting medium (Sigma, F4680) was placed on the top of labeled 
plates. The coverslip was retrieved from the well and placed with cell side down on top 
of the drop of mounting medium by using forceps. Bubbles between the coverslip and the 
plate were avoided by gently pressing the center of the coverslip with forceps. Mounted 
slides were stored in an opaque box to let the mounting medium dry and fix for 30 min.  
2.8.6 Detection and Analysis  
Fluorescence was detected by a Nikon 
microscope (ECLIPSE TE-2000E) and 
images were acquired by SimplePCI 
image software from Hamamatsu 
Corporation. Five different areas were 
chosen to count the staining cells on 
each coverslip. All slides were kept in 
dark sample boxes and put at -20°C for 
long-term storage. Analysis of 
fluorescent micrographs was conducted 
by using Image-Pro Plus software from 
Media Cybernetics, Inc. 
 
Figure 2.1 Areas of cell counting in 
immunocytochemical staining 
 
2.9 Western Blotting 
Western blotting is a very sensitive and efficient assay to detect small amount of proteins. 
Extracted proteins from samples are separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and then transferred from the gel to a membrane by 
electroblotting. Finally, the proteins on the membrane are detected by using primary and 
secondary antibodies and a chemiluminescent reagent. 
 
 
32 
 
33 
 
2.9.1 Sample Preparation 
Cells were seeded at the density of 5 x 104 cells/cm2 in differentiation medium in 6-well 
tissue culture plates for up to 96 h to ensure enough amounts of cells for protein 
extraction. Each well was assigned for a specific concentration of hyperforin treatment. 
Six samples from one 6-well plate were used for western blotting assay at the same time 
on the same polyvinylidene fluoride (PVDF) membrane and with the same assay 
parameters.  
2.9.1.1 Extraction of Protein 
The 6-well tissue culture plate was removed from 37°C incubator and placed on ice. The 
culture medium was removed by pipetting. Adherent cells were washed with 3 mL of 
0.01 M ice-cold PBS once. After washing, 70 µL of ice-cold lysis buffer was added into 
each well. The lysis buffer consisted of RIPA solution and 1% of protease inhibitor 
cocktail (Sigma, P8340). Adherent cells were scraped off plates using a plastic cell 
scraper. The cell lysate was then transferred into a cool 1.5 mL eppendorf tube and 
maintained in ice for 30 min. The cell lysate was centrifuge at 10,000 x g for 15 min at 
4°C. The supernatant was transferred into a fresh 1.5 mL eppendorf tube and placed on 
ice. 
2.9.1.2 Quantitation of Protein 
The concentrations of proteins were quantified with BCA Protein Assay Kit (Pierce, 
23227). Bovine serum albumin (BSA) was used as a standard in the assay. 10 µL of each 
protein sample was used for this assay. The concentrations of all samples were adjusted 
to 1000 µg/mL. The final loading concentrations were adjusted to 800 µg/mL with 5X 
loading buffer. The protein samples were denatured in a boiling water bath for 10 min. 
After being denatured, the protein samples were mixed thoroughly either for 
electrophoresis or for long-term storage at -80°C. 
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2.9.2 Acrylamide Gel Preparation and Electrophoresis 
2.9.2.1 Acrylamide Gel Preparation 
SDS-PAGE is used for separating proteins according to their molecular weights. The 
separation of molecules within a gel is determined by the relative size of the pores 
formed within the gel. The pore size of a gel is determined by two factors: the total 
amount of acrylamide present and the amount of cross-linker. In this study, 10% of 
acrylamide gels produced from 30% Acrylamide/Bis Solution, 29: 1 ratio (Bio-Rad, 161-
0157) were used for separating proteins with molecular weights between 15 kDa and 100 
kDa. A glass plate sandwich was assembled on a casting stand, and the gel was poured 
into the space between the plates. 10% separating gels and 4% stacking gels were 
prepared freshly (Table 2.3). Volumes were for two gels with the Bio-Rad Mini-
PROTEAN system.  
Table 2.3 Recipes of separating gel and stacking gel for SDS-PAGE 
Components 10% separating gel 4% stacking gel 
30% Acrylamide 2.50 mL 0.67 mL 
ddH2O 4.06 mL 2.97 mL 
1.5 M Tris-HCl, pH 8.8 3.33 mL 0.00 mL 
0.5 M Tris-HCl, pH 6.8 0.00 mL 1.25 mL 
10% SDS 100 µL 50 µL 
10% ammonium persulfate 100 µL 100 µL 
Tetramethylethylenediamine 10 µL 5 µL 
2.9.2.2 Electrophoresis 
The electrophoresis system was assembled according to the instruction. Running buffer 
was poured into the chamber to merge the top and bottom of the gel for electric current to 
flow through the gel. The comb was removed, and the wells were rinsed with Running 
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buffer. Protein samples (25 µL) were loaded in wells with loading tips. Pre-stained 
molecular weight marker (7 µL) - (Fisher, BP36031) was loaded with 18 µL of 1X 
loading buffer in a well. Unused wells were loaded with 25 µL of 1X loading buffer. The 
two-gel electrophoresis system was run at 70 V of constant voltage for 2.5 h until the 
bromophenol blue dye reached the bottom of the gels. 
2.9.3 Electroblotting and Blocking 
The glass sandwich was removed from the electrophoresis tank after the electrophoresis. 
The short plate was taken off from the glass sandwich, and then the stacking gel was cut 
off from the separating gel. The separating gel was gently transferred from the glass plate 
onto a filter paper in a tray containing 1X Transfer buffer. A PVDF membrane, pre-
treated with methanol for 5 min, was put on the top of the gel avoiding bubbles, and then 
another filter paper was put on the PVDF membrane. The gel and PVDF membrane were 
put into a sandwich and two sandwiches were put into a Bio-Rad electroblotting system 
containing 1X Transfer buffer. The two-gel electroblotting system was run at 200 mA of 
constant current for 1.5 h. The electroblotting system was put in an ice-water bath with 
ice covering the whole electroblotting tank in order to remove the heat during the 
transferring process. To check the success of electroblotting, the membrane was washed 
in Tris-Buffered Saline Tween-20 (TBST) briefly and put into Ponceau S solution (0.1% 
Ponceau S in 5% acetic acid) at 1: 10 dilution. The red protein bands showed up after 
extensive washing in water. The membrane was destained completely by washing it in 
TBST for three times, 5 min for each wash.  
2.9.4 Immunodetection 
2.9.4.1 Blocking the Membrane 
Blocking prevented non-specific background binding of the primary and secondary 
antibodies to the membrane. The 5% of skim milk in TBST was used to block 
membranes for 1 h with gentle shaking at room temperature.  
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2.9.4.2 Incubation with Primary and Secondary Antibodies 
The primary antibody was diluted with 5% of skim milk in TBST at the proper 
concentration. The primary antibody was incubated at 4°C overnight with gentle shaking. 
After the incubation with primary antibody, the membrane was washed with TBST at 
room temperature for three times, 15 min for each wash. The horseradish peroxidase-
conjugated secondary antibody was diluted with 5% of skim milk in TBST at dilution of 
1:5000. The secondary antibody was incubated at room temperature for 1 h with gentle 
shaking. After the incubation with secondary antibody, the membrane was washed with 
TBST at room temperature for three times, 15 min for each wash. 
2.9.4.3 Chemiluminescence Detection 
After the final wash, TBST was drained as much as possible. The membrane was 
incubated with electrochemiluminescence (ECL) solution (PerkinElmer, NEL104) for 2 
min at room temperature. After incubation, the membrane was picked up with forceps, 
and the ECL solution was drained as much as possible by allowing the membrane to 
touch a paper towel. The membrane was put between two sheets of plastic wrap to 
prevent X-ray films from getting wet. The signal was recorded by exposing the 
membrane to an X-ray film in a dark room. Manual film development was carried out by 
putting the X-ray film in the developing agent (Sigma, P7042) and fixation agent (Sigma, 
P7167). The developed X-ray films were scanned by Fluorchem 8900 from Alpha 
Innotech. The Quantity One software was used to analyze the signals of grayscale images. 
The β-actin was used as the loading control to analyze the relative strength of signals.  
2.9.5 Buffer Recipes 
RIPA Buffer 
Sodium chloride     150 mM 
Triton X-100      1.0% 
Sodium deoxycholate     0.5% 
37 
 
SDS       0.1% 
Tris, pH 8.0      50 mM 
 
4X loading buffer  
1M Tris pH=6.8     2 mL 
Glycerol      4 mL 
β-mercaptoethanol     2 mL 
Bromophenol blue     30 mg 
SDS       800 mg 
Total volume      10 mL 
Aliquot into 1mL aliquots and stored at -20°C 
 
1.5 M Tris pH=8.8 
Tris        18.17 g 
0.1% SDS      4 mL 
Adjust pH=8.8 with 12N HCL  
Make to 100mL with ddH2O 
 
0.5 M Tris pH=6.8 
Tris        6.06 g 
0.1% SDS      4 mL 
Adjust pH=6.8 with 12N HCL  
Make to 100mL with ddH2O 
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10X Running buffer    
Tris       30 g 
Glycine       144 g 
SDS       10 g 
Make to 1 liter with ddH2O     
 
1X Running buffer  
10X Running buffer      100 mL 
ddH2O       900mL 
 
10X Transfer buffer  
Tris       30 g 
Glycine       144 g 
Make to 1 liter with ddH2O 
 
1X Transfer buffer 
10X Transfer buffer     100 mL 
Methanol      100 mL 
ddH2O       800 mL 
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2.10 Statistical Analysis 
All the raw data from each assay were used for statistical analysis. All results were 
expressed as Mean ± SEM. Most of the data were expressed as a relative percentage of 
the control. The immunocytochemical staining data of MBP, Olig2, GFAP and β-III 
tubulin were expressed as ratios of positive staining cells to total cells. The dose-response 
relationships were analyzed by one-way ANOVAs followed by Bonferroni / Dunn’s post-
hoc test. The effects of hyperforin and rotenone on CG-4 cells were analyzed by two-way 
ANOVA followed by Bonferroni / Dunn’s post-hoc test.  Values of p < 0.05 were 
considered statistically significant. The software GB-STAT was used to do statistical 
analysis. 
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3 RESULTS 
3.1 Effect of Hyperforin on the Proliferation of CG-4 Cells 
and NS/PCs 
Tetrazolium salts have been widely applied to evaluate cell viability, cell proliferation 
and cytotoxicity for decades (Mosmann, 1983). MTT and WST-8 are two most 
extensively used tetrazolium salts. It is generally believed that MTT is reduced by 
accepting electrons from a variety of intracellular reductants, such as nicotinamide 
adenine dinucleotide (NADH) and succinate. WST-8 is reduced primarily at the cell 
surface by accepting trans-plasma electrons driven by intracellular NADH from the 
mitochondrial citric acid cycle (Berridge et al., 2005). Both reduction processes are 
dependent on the cellular redox activity, so the reduced formazans from tetrazolium salts 
are correlated to mitochondrial function (Berridge and Tan, 1993). MTT assay is usually 
applied in endpoint assays, because MTT is reduced to form an insoluble formazan. 
WST-8 assay is usually applied in real time assays, because WST-8 is reduced to form a 
soluble formazan. To examine whether hyperforin increased the genesis of 
oligodendrocyte progenitors and NS/PCs, MTT assay and WST-8 assay were used to 
measure the cell viabilities of proliferating CG-4 cells and NS/PCs, because usually the 
reduction of MTT or WST-8 is proportional to the number of viable cells in the 
exponential growth phase (Berridge et al., 2005).  
3.1.1 Hyperforin Did Not Affect the Cell Viability of Proliferating CG-4 
Cells at Concentrations between 0.0 μM and 0.1 μM but Inhibited 
the Cell Viability of Proliferating CG-4 Cells at Higher 
Concentrations 
We found hyperforin did not change the cell viability of proliferating CG-4 cells by MTT 
assay at concentrations between 0.0 μM and 0.5 μM for 24 h and between 0.0 μM and 0.1 
μM for 48 h. (Figure 3.1 and Figure 3.2). However, at higher concentrations, hyperforin 
decreased the total cell viability at 1.0 μM (43.8% ± 8.3% of the value at 0.0 μM) for 24 
h; and at 0.5 μM (21.1% ± 2.4% of the value at 0.0 μM) and at 1.0 μM (8.2% ± 1.4% of 
the value at 0.0 μM) for 48 h compared to 0.0 μM of hyperforin. (Figure 3.1 and Figure 
3.2).  
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Figure 3.1 Cell viability of proliferating CG-4 cells after 24 h of hyperforin 
treatment by MTT assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 24 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=4). HF: Hyperforin. 
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Figure 3.2 Cell viability of proliferating CG-4 cells after 48 h of hyperforin 
treatment by MTT assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=4). HF: Hyperforin. 
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3.1.2 Hyperforin Did Not Affect the Cell Viability of Proliferating 
NS/PCs at Concentrations between 0.0 μM and 2.5 μM 
We found hyperforin did not change the cell viability of proliferating NS/PCs by WST-8 
assay at concentrations between 0.0 μM and 2.5 μM for both 24 h and 48 h. (Figure 3.3 
and Figure 3.4).  
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Figure 3.3 Cell viability of proliferating NS/PCs after 24 h of hyperforin treatment 
by WST-8 assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 24 h using WST-8 assay. All groups were compared to 0.0 μM 
of hyperforin (Mean ± SEM, n=3). HF: Hyperforin. 
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Figure 3.4 Cell viability of proliferating NS/PCs after 48 h of hyperforin treatment 
by WST-8 assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h using WST-8 assay. All groups were compared to 0.0 μM 
of hyperforin (Mean ± SEM, n=4). HF: Hyperforin. 
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3.2 Effects of Hyperforin on Mitochondrial Function in 
Differentiating CG-4 Cells and NS/PCs  
The differentiation of CG-4 cells or NS/PCs was initiated by replacing the growth 
medium with the differentiation medium. Usually, CG-4 cells began to show 
morphological characteristics of mature oligodendrocytes within two days (Stariha and 
Kim, 2001); NS/PCs began to show different types of neural cell markers within four 
days when maintained in the differentiation medium. 
During the differentiation processes of CG-4 cells and NS/PCs, a series of assays were 
used to evaluate the effects of hyperforin on the mitochondrial function of differentiating 
CG-4 cells and NS/PCs. The tetrazolium microplate assays including the MTT assay and 
the WST-8 assay were used to measure the NADH levels generated from glycolysis and 
the citric acid cycle. ATP is the main energy resource for most cell functions, including 
biological synthesis, transporting macromolecules and cell signaling. Mitochondria are 
the major cellular source of ATP synthesis in mammal cells and 95% of the energy 
supply is from mitochondrial oxidative phosphorylation. Intracellular ATP levels are 
considered the most sensitive end points in understanding characteristics of cellular 
energy metabolism and mitochondrial function in both physiological and pathological 
states (Maehara et al., 1987). The firefly luciferase ATP assay was used to directly 
measure the intracellular levels of ATP. There is a proton gradient across the inner 
mitochondrial membrane. This proton gradient is the result of proton pumping during the 
electron transport in the mitochondria (Boyer et al., 1977; Mitchell, 1966). This proton 
gradient generates membrane potential and pH gradient across the inner membrane. The 
potential energy stored in these two gradients drives the ATP synthase to generate ATP 
from adenosine diphosphate (ADP) and inorganic phosphate (Pi) (Boyer, 1987; Mitchell, 
1979), which is the last step of oxidative phosphorylation. Mitochondrial membrane 
potential is an important parameter regulated by the demand of living cells. It represents 
the bioenergetic state of living cells. Rhodamine123 is actively transported into the 
mitochondria but it can not freely pass through the membrane (Haydon and Hladky, 
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1972), so it accumulates in mitochondria proportionally to the mitochondrial membrane 
potential. Rhodamine123 assay was used to measure the mitochondrial membrane 
potential. This assay can further support that increased ATP generation was related to the 
increased potential energy in mitochondria rather than other reasons, for example, the 
decrease of ATP consumption. 
3.2.1 Effects of Hyperforin on Mitochondrial Function-related 
Parameters and Cell Numbers of Differentiating CG-4 Cells at 
Different Concentrations  
3.2.1.1 MTT and WST-8 Assays 
In differentiating CG-4 cells, hyperforin significantly increased cell viability by MTT 
assay at 0.25 μM (119.9% ± 4.1% of the value at 0.0 μM) and at 0.5 μM (124.2% ± 2.6% 
of the value at 0.0 μM) for 24 h (Figure 3.5); as well as at 0.25 μM (122.5% ± 2.9% of 
the value at 0.0 μM) and at 0.5 μM (131.6% ± 2.5% of the value at 0.0 μM) for 48 h 
(Figure 3.6) compared to 0.0 μM of hyperforin. Hyperforin also significantly increased 
cell viability by WST-8 assay at 0.5 μM (132.0% ± 5.9% of the value at 0.0 μM) for 24 h 
(Figure 3.7); as well as at 0.125 μM (122.2% ± 4.9% of the value at 0.0 μM) and at 0.5 
μM (162.8% ± 2.4% of the value at 0.0 μM) for 48 h (Figure 3.8) compared to 0.0 μM of 
hyperforin.  Hyperforin did not significantly affect the cell viability at 1.0 μM for 24 h of 
treatment, but it significantly decreased the cell viability at 1.0 μM  (76.4% ± 2.3% of the 
value at 0.0 μM) for 48 h compared to 0.0 μM of hyperforin by WST-8 assay (Figure 
3.8). 
  
 
HF0.0 HF0.0625 HF0.125 HF0.25 HF0.5 HF1.0
60
80
100
120
140
Hyperforin (μM)
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
 (%
) ****
 24h
 
Figure 3.5 Cell viability of differentiating CG-4 cells after 24 h of hyperforin 
treatment by MTT assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 24 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=6). HF: Hyperforin. 
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Figure 3.6 Cell viability of differentiating CG-4 cells after 48 h of hyperforin 
treatment by MTT assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=6). HF: Hyperforin. 
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Figure 3.7 Cell viability of differentiating CG-4 cells after 24 h of hyperforin 
treatment by WST-8 assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 24 h using WST-8 assay. All groups were compared to 0.0 μM 
of hyperforin and *p < 0.05 (Mean ± SEM, n=3). HF: Hyperforin. 
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Figure 3.8 Cell viability of differentiating CG-4 cells after 48 h of hyperforin 
treatment by WST-8 assay 
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h using WST-8 assay. All groups were compared to 0.0 μM 
of hyperforin and **p < 0.01 (Mean ± SEM, n=3). HF: Hyperforin. 
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3.2.1.2 Intracellular ATP Levels 
In differentiating CG-4 cells, hyperforin significantly increased intracellular ATP levels 
at 0.25 μM (132.0% ± 6.6% of the value at 0.0 μM) and at 0.5 μM (134.5% ± 6.8% of the 
value at 0.0 μM) for 24 h (Figure 3.9); as well as at 0.125 μM (121.9% ± 4.2% of the 
value at 0.0 μM), at 0.25 μM (123.7% ± 4.9% of the value at 0.0 μM) and at 0.5 μM 
(132.3% ± 5.7% of the value at 0.0 μM) for 48 h compared to 0.0 μM of hyperforin 
(Figure 3.10). However, hyperforin significantly decreased intracellular ATP levels at 
1.0 μM (32.0% ± 3.0% of the value at 0.0 μM) for 48 h compared to 0.0 μM of 
hyperforin (Figure 3.10). 
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Figure 3.9 Intracellular ATP levels in differentiating CG-4 cells after 24 h of 
hyperforin treatment 
51 
 
Intracellular ATP levels expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
at escalating doses from 0.0 μM to 1.0 μM for 24 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05 (Mean ± SEM, n=8). HF: Hyperforin. 
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Figure 3.10 Intracellular ATP levels in differentiating CG-4 cells after 48 h of 
hyperforin treatment 
Intracellular ATP levels expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
*p < 0.05, **p < F: Hyperforin. 
at escalating doses from 0.0 μM to 1.0 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and 
0.01 (Mean ± SEM, n=8). H
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3.2.1.3 Rhodamine123 Uptake 
In differentiating CG-4 cells, hyperforin significantly increased Rhodamine123 uptake at 
0.125 μM (119.5% ± 2.5% of the value at 0.0 μM), at 0.25 μM (119.1% ± 1.6% of the 
value at 0.0 μM)  and at 0.5 μM (119.5% ± 5.4% of the value at 0.0 μM) for 24 h (Figure 
3.11); as well as at 0.125 μM (130.0% ± 4.7% of the value at 0.0 μM), at 0.25 μM 
(134.5% ± 5.2% of the value at 0.0 μM) and at 0.5 μM (123.7% ± 5.7% of the value at 
0.0 μM) for 48 h compared to 0.0 μM of hyperforin (Figure 3.12). However, hyperforin 
significantly decreased Rhodamine123 uptake at 1.0 μM (62.6% ± 2.5% of the value at 
0.0 μM) for 24 h (Figure 3.11); as well as at 1.0 μM (33.2% ± 3.6% of the value at 0.0 
μM) for 48 h compared to 0.0 μM of hyperforin (Figure 3.12). 
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Figure 3.11 Rhodamine123 uptake in differentiating CG-4 cells after 24 h of 
hyperforin treatment 
Rhodamine123 uptake expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
at escalating doses from 0.0 μM to 1.0 μM for 24 h. All groups were compared to 0.0 μM of hyperforin and 
**p < 0.01 (Mean ± SEM, n=7). HF: Hyperforin. 
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Figure 3.12 Rhodamine123 uptake in differentiating CG-4 cells after 48 h of 
hyperforin treatment  
Rhodamine123 uptake expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
at escalating doses from 0.0 μM to 1.0 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05, **p < 0.01(Mean ± SEM, n=7). HF: Hyperforin. 
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3.2.1.4 BrdU Incorporation and Viable Cell Number 
CG-4 cells began to differentiate in the differentiation medium, but they can still maintain 
a certain ability to increase cell numbers, because certain portion of CG-4 cells are still in 
the cell-division cycle (Louis et al., 1992). BrdU assay and viable cell number counting 
were used to exclude the possibility that the increased cell viability was due to the lower 
level of cell proliferation.  
In differentiating CG-4 cells, hyperforin did not significant change BrdU incorporation 
(Figure 3.13 and Figure 3.14) and total CG-4 cell numbers (Figure 3.15) at 
concentrations between 0.0 μM and 0.5 μM for 24 h and 48 h. However, hyperforin 
significantly decreased BrdU incorporation at 1.0 μM (44.1% ± 4.3% of the value at 0.0 
μM) for 48 h; as well as the viable cell numbers at 0.75 μM (66.2% ± 5.6% of the value 
at 0.0 μM) and at 1.0 μM (47.2% ± 5.7% of the value at 0.0 μM) for 48 h compared to 0.0 
μM of hyperforin (Figure 3.15).  
These results demonstrated that hyperforin increased mitochondrial function-related 
parameters in differentiating CG-4 cells without affecting the viable cell numbers at 
concentrations between 0.25 μM and 0.5 μM for both 24 h and 48 h compared to 0.0 μM 
of hyperforin. Hyperforin significantly decreased most mitochondrial function-related 
parameters, BrdU incorporation as well as the viable cell number at 1.0 μM for 48 h 
compared to 0.0 μM of hyperforin.  
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Figure 3.13 BrdU incorporation in differentiating CG-4 cells after 24 h of 
hyperforin treatment  
BrdU incorporation expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 24 h. All groups were compared to 0.0 μM of hyperforin 
(Mean ± SEM, n=3). HF: Hyperforin. 
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Figure 3.14 BrdU incorporation in differentiating CG-4 cells after 48 h of 
hyperforin treatment  
BrdU incorporation expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05 (Mean ± SEM, n=3). HF: Hyperforin. 
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Figure 3.15 Viable cell numbers in differentiating CG-4 cell culture after 48 h of 
hyperforin treatment 
Viable cell numbers expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 1.0 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05, **p < 0.01 (Mean ± SEM, n=4). HF: Hyperforin. 
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3.2.2 Hyperforin Prevented Rotenone-induced ATP Depletion in 
Differentiating CG-4 Cells 
Rotenone is a potent natural cytotoxic compound extracted from tropical plants and is 
commonly used as an insecticide. Rotenone is extremely lipophilic, so it is able to freely 
cross cellular membranes and accumulate in mitochondria (Talpade et al., 2000), where it 
impairs oxidative phosphorylation by inhibiting complex I of the mitochondrial electron-
transport chain (Schuler and Casida, 2001). Rotenone-induced inhibition of complex I 
causes acute ATP depletion and generation of reactive oxygen species (ROS). Increased 
oxidative stress can damage mitochondrial DNA and proteins to induce apoptosis (Sherer 
et al., 2003). Rotenone is now used as a classical inhibitor of complex I in cell culture and 
experimental animal models (Betarbet et al., 2000).  
In differentiating CG-4 cells, 24 h insult of rotenone showed a dose-dependent trend to 
significantly decrease the intracellular ATP levels at concentrations of 31.25 nM (58.4% 
± 3.7% of the control value), 62.5 nM (40.1% ± 2.7% of the control value) and 125 nM 
(27.8% ± 3.0% of the control value) compared to control. Consistently, 48 h treatment of 
hyperforin significantly increased the intracellular ATP level at 0.25 μM (136.0% ± 7.5% 
of the control value) compared to control. We pretreated CG-4 cells with 0.25 μM of 
hyperforin for 24 h, and then we introduced the insults of different concentrations of 
rotenone to evaluate the protective effect of hyperforin on rotenone-induced cytotoxicity. 
During the 24 h insult of the rotenone, the hyperforin pretreatment remained in the 
culture medium. 
Our results indicated that pretreatment with hyperforin at 0.25 μM for 24 h significantly 
prevented the decrease of the intracellular ATP level induced by the insult of rotenone at 
31.25 nM (Figure 3.16). The protective effect of hyperforin maintained the intracellular 
ATP at the level (83.1% ± 6.4% of the control value) which was not significantly 
different from that of control. However, hyperforin was not able to prevent the decrease 
of the intracellular ATP level induced by insults of rotenone at 62.5 nM and 125 nM. 
Although hyperforin tended to prevent the ATP depletion in these groups, there were no 
significant differences in intracellular ATP levels between the hyperforin pretreatment 
groups and rotenone only groups. 
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Figure 3.16 Intracellular ATP levels in differentiating CG-4 cells after 24 h 
pretreatment of hyperforin and 24 h insult of rotenone 
Intracellular ATP levels expressed as a percentage of the control after pretreatment with hyperforin at 0.25 
μM for 24 h and insults of rotenone from 31.25 nM to 125 nM for another 24 h. During the 24 h insult of 
the rotenone, the hyperforin pretreatment remained in the culture medium. **p < 0.01 compared to RT 
31.25 nM; ## p < 0.01 compared to CTL (Mean ± SEM, n=8). CTL: control; HF: hyperforin; RT: rotenone.  
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3.2.3 Effects of Hyperforin on Mitochondrial Function-related 
Parameters of Differentiating NS/PCs at Different Concentrations 
3.2.3.1 MTT Assay 
In differentiating NS/PCs, hyperforin significantly increased the cell viability by MTT 
assay at 5.0 μM (125.9% ± 5.1% of the value at 0.0 μM) for 24 h (Figure 3.17); as well 
as at 2.5 μM (127.9% ± 3.6% of the value at 0.0 μM) and at 5.0 μM (144.1% ± 6.4% of 
the value at 0.0 μM) for 48 h compared to 0.0 μM of hyperforin (Figure 3.18). 
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Figure 3.17 Cell viability of differentiating NS/PCs after 24 h of hyperforin 
treatment  
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 10 μM for 24 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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Figure 3.18 Cell viability of differentiating NS/PCs after 48 h of hyperforin 
treatment  
Cell viability expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 μM to 10 μM for 48 h using MTT assay. All groups were compared to 0.0 μM of 
hyperforin and **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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3.2.3.2 Intracellular ATP Levels 
In differentiating NS/PCs, hyperforin significantly increased intracellular ATP levels at 
5.0 μM (129.2% ± 2.9% of the value at 0.0 μM) for 24 h (Figure 3.19); as well as at 2.5 
μM (117.4% ± 5.3% of the value at 0.0 μM) and at 5.0 μM (120.6% ± 2.5% of the value 
at 0.0 μM) for 48 h compared to 0.0 μM of hyperforin (Figure 3.20). However, 
hyperforin significantly decreased intracellular ATP levels at 10 μM (72.9% ± 8.6% of 
the value at 0.0 μM) for 24 h and at 10 μM (77.8% ± 1.2% of the value at 0.0 μM) for 48 
h compared to 0.0 μM of hyperforin (Figure 3.19 and Figure 3.20). 
These results indicated that hyperforin increased cell viability and intracellular ATP 
levels in differentiating NS/PCs cells at concentrations between 2.5 μM and 5.0 μM for 
24 h and 48 h. Hyperforin decreased the intracellular ATP levels at the concentration of 
10 μM for 24 h and 48 h. 
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Figure 3.19 Intracellular ATP levels in differentiating NS/PCs after 24 h of 
hyperforin treatment 
Intracellular ATP levels expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
at escalating doses from 0.0 μM to 10 μM for 24 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05, **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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Figure 3.20 Intracellular ATP levels in differentiating NS/PCs after 48 h of 
hyperforin treatment 
Intracellular ATP levels expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin 
at escalating doses from 0.0 μM to 10 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and 
*p < 0.05, **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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3.3 Effects of Hyperforin on Development of Oligodendrocytes 
in Differentiating NS/PCs  
3.3.1 Characterization and Differentiation of NS/PCs 
Nestin is a class VI intermediate filament protein with a molecular weight of 198 kDa 
(Hockfield and McKay, 1985; Lendahl et al., 1990). It is expressed predominantly in 
NS/PCs of the central nervous system (Frederiksen and McKay, 1988). Nestin has been 
observed in cells of nervous tissue formation during the embryonic period of ontogenesis, 
in various neural precursors and in cells of various nervous system tumors (Gilyarov, 
2008; Uchida et al., 2000). Nestin has been the most extensively used marker to identify 
NS/PCs within developing nervous system and in cultured cells.  
CNPase is a 46 kDa protein comprising 4 % of total myelin proteins (Vogel and 
Thompson, 1988). CNPase may play an initial role in oligodendrocyte differentiation. 
Studies on the developmental expression of CNPase indicate that CNPase appears in 
early myelination and is maintained at a high level as myelin is produced (Sprinkle et al., 
1978). It is enriched in CNS myelin and oligodendrocytes, so it is commonly used as a 
marker for myelinating oligodendrocytes. 
GFAP is an intermediate filament protein with a molecular weight of 50 kDa. GFAP is 
the major protein constituent of glial cytoskeletal filaments in differentiated astrocytes of 
the CNS. GFAP plays an important role in modulating astrocyte motility and shape by 
providing structural stability to extensions of astroglial processes (Eng et al., 2000). 
GFAP has proven to be a reliable marker for normal and neoplastic cells of astroglial 
lineage.  
β-III tubulin is one of the subunit protein of microtubules with a molecular weight of 50 
kDa. β-III tubulin expression was originally used as a marker of the early phase of 
neuronal differentiation in human embryonic development (Luduena, 1998).   
The fast proliferating neurospheres in growth medium were stained by NS/PCs marker 
nestin. Different cell type specific markers including CNPase, GFAP and β-III tubulin 
were used to detect different cell lineages including oligodendrocytes, astrocyte and 
neurons. The nuclei were stained with Hoechst 33342. All the fluorescent 
microphotographs from immunocytochemical staining showed that most of the 
proliferating cells in neurospheres were NS/PCs, and they were able to differentiate into 
different cell lineages of oligodendrocytes, astrocyte and neurons after 72 h of 
differentiation (Figure 3.21). 
 
Figure 3.21 Fluorescent microphotographs of proliferating NS/PCs and 
differentiating NS/PCs  
Neurospheres were maintained in growth medium for 4 h to allow attachment to the Poly-D-Lysine coated 
coverslip before proceeding the immunocytochemical staining. Differentiating NS/PCs were maintained in 
differentiation medium for 72 h before proceeding the immunocytochemical staining. The scale bar 
represents 50 µm. 
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3.3.2 Hyperforin Increased Expressions of Proteins Related to 
Oligodendrocyte Development but not the Ratio of 
Oligodendrocyte Lineage Cells in Differentiating NS/PCs 
MBP is a structural protein essential for formation of CNS myelin membranes, which 
optimizes transmission of action potentials in axons by saltatory conduction. It comprises 
30% of the total protein of myelin (Harauz et al., 2004). MBP presents both in the CNS 
and peripheral nervous system (PNS) with a variety of isoforms. There are four isoforms 
of 21.5 kDa, 20.2 kDa, 18.5 kDa, and 17.2 kDa in humans and four isoforms of 21.5 kDa, 
18.5 kDa, 17.0 kDa and 14.0 kDa in rat (Boggs, 2006). MBP plays a key role in the 
formation of compact myelin by bringing the cytoplasmic surfaces of the myelin 
membrane together (Jacobs, 2005). MBP has been extensively used as a mature 
oligodendrocyte marker. MBP and CNPase were used in this study to indentify the 
premature and mature oligodendrocytes in the differentiating NS/PC system. By 
comparing the expressions of both proteins in different hyperforin treatment groups, we 
were able to determine the effect of hyperforin on the development process of 
oligodendrocytes.  
Oligodendrocyte lineage transcription factor 2 (Olig2), is a basic helix-loop-helix 
transcription factor essential for oligodendrocyte lineage determination. It is specific to 
the oligodendrocyte lineage during the early stage of CNS development (Rowitch et al., 
2002). Expression of Olig2 is before the expression of early oligodendrocyte progenitor 
marker, such as PDGF receptor-α (Stolt et al., 2002). Therefore, Olig2 is considered the 
earliest marker available so far for oligodendrocyte lineage. Olig2 was used to determine 
how many NS/PCs became oligodendroglial lineage cells in differentiating NS/PCs. The 
expression of Olig2 was also used to evaluate the extent of maturation of 
oligodendrocytes because of its close relationship to this process (Lu et al., 2000).  
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3.3.2.1 Hyperforin Increased both Ratios of MBP-positive Cells and Expressions of 
MBP in Differentiating NS/PCs 
MBP expressions were detectable by immunocytochemical staining in NS/PCs after 96 h 
of differentiation (Figure 3.22). Hyperforin caused no difference on total viable cell 
numbers at concentrations between 0.0 μM and 2.5 μM for 96 h (Table 3.1 and Figure 
3.24). Hyperforin significantly increased ratios of MBP-positive cells in differentiating 
NS/PCs at concentrations of 0.625 μM (4.1% ± 0.3%) and 1.25 μM (4.5% ± 0.5%) for 96 
h compared to 0.0 μM (2.1% ± 0.1%) of hyperforin (Table 3.1, Figure 3.23 and Figure 
3.25). Hyperforin increased ratios of MBP-positive cells by increasing the numbers of 
MBP-positive cells rather than decreasing the total viable cell numbers (Table 3.1). 
Accordantly, hyperforin significantly increased expressions of MBP (two bands detected 
by goat anti-MBP) in differentiating NS/PCs at concentrations of 0.625 μM (180.8% ± 
12.7% of the value at 0.0 μM) and 1.25 μM (185.8% ± 15.8% of the value at 0.0 μM) for 
96 h compared to 0.0 μM of hyperforin as determined by Western blot (Figure 3.26). 
Hyperforin did not significantly affect either ratios of MBP-positive cells or expressions 
of MBP at other concentrations in this study. 
  
 
 
Figure 3.22 Fluorescent microphotographs of NS/PCs expressing MBP after 96 h of 
differentiation 
The scale bar represents 50 µm. 
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 Figure 3.23 Fluorescent microphotographs of differentiating NS/PCs expressing 
MBP after 96 h of differentiation with hyperforin treatment  
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h in differentiation 
medium. NS/PCs were stained with Hoechst 33342 (blue) and MBP (red). HF: Hyperforin. The scale bar 
represents 500 µm. 
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Table 3.1 Ratios of MBP-positive cells to total NS/PCs after 96 h of hyperforin 
treatment 
Experiment Description HF0.0µM HF0.15625µM HF0.3125µM HF0.625µM HF1.25µM HF2.5µM 
1 
Total cells 996.4 1029.8 988.8 1030.2 999.0 989.8 
MBP+ cells 21.4 33.0 29.0 39.6 49.6 32.2 
Ratio 2.2% 3.2% 2.9% 3.8% 5.0% 3.3% 
2 
Total cells 965.5 986.8 952.8 826.8 886.8 883.8 
MBP+ cells 21.8 25.8 26.4 28.2 40.0 20.2 
Ratio 2.2% 2.6% 2.8% 3.4% 4.5% 2.3% 
3 
Total cells 983.5 956.5 901.6 980.5 911.8 910.4 
MBP+ cells 22.5 15.3 22.0 47.3 34.6 16.4 
Ratio 2.3% 1.6% 2.4% 4.8% 3.8% 1.8% 
4 
Total cells 924.0 852.0 874.4 895.0 801.0 760.6 
MBP+ cells 17.5 17.2 19.4 34.3 24.3 9.2 
Ratio 1.9% 2.0% 2.2% 3.8% 3.0% 1.2% 
5 
Total cells 863.0 863.2 844.2 880.8 924.0 876.8 
MBP+ cells 15.4 23.6 35.2 41.2 55.8 15.2 
Ratio 1.8% 2.7% 4.2% 4.7% 6.0% 1.7% 
Mean ± SEM 
Total cells 946.5±24.2 937.6±34.7 912.4±26.2 922.7±36.5 904.5±31.9 884.3±36.9 
MBP+ cells 19.7±1.4 23.0±3.2 26.4±2.8 38.1±3.2* 40.8±5.5** 18.6±3.8 
Ratio 2.1% ±0.1% 2.4% ±0.3% 2.9% ±0.3% 4.1% ±0.3%** 4.5% ±0.5%** 2.1% ±0.3% 
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. All groups were 
compared to 0.0 μM of hyperforin and *p < 0.05, **p < 0.01 (Mean ± SEM, n=5). HF: hyperforin. 
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Figure 3.24 Total viable cell numbers of NS/PCs after 96 h of differentiation with 
hyperforin treatment  
Total viable cell number expressed as a percentage of the number at HF 0.0 μM after treatment with 
hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. All groups were compared to 0.0 μM of 
hyperforin (Mean ± SEM, n=5). HF: Hyperforin. 
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Figure 3.25 Ratios of MBP-positive cells to total NS/PCs after 96 h of differentiation 
with hyperforin treatment  
Ratios of MBP-positive cells were calculated after treatment with hyperforin at escalating doses from 0.0 
μM to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin and **p < 0.01 (Mean ± SEM, 
n=5). HF: Hyperforin. 
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Figure 3.26 Chemiluminescent detections of MBP and β-actin in NS/PCs after 96 h 
of differentiation with hyperforin treatment 
MBP expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin and **p < 
0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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3.3.2.2 Hyperforin Increased Expressions of CNPase in Differentiating NS/PCs  
Hyperforin significantly increased expressions of CNPase at concentrations of 0.625 μM 
(183.4 ± 13.3% of the value at 0.0 μM), 1.25 μM (194.0 ± 14.5% of the value at 0.0 μM) 
and 2.5 μM (181.5 ± 20.6% of the value at 0.0 μM) for 48 h compared to 0.0 μM of 
hyperforin as determined by Western blot (Figure 3.27). Hyperforin significantly 
increased the CNPase expression at 0.3125 μM (158.2 ± 15.9% of the value at 0.0 μM) 
and 0.625 μM (161.5 ± 14.8% of the value at 0.0 μM) for 96 h compared to 0.0 μM of 
hyperforin (Figure 3.28). Although the CNPase expressions were maintained at high 
levels after hyperforin treatment at 1.25 μM and 2.5 μM for 96 h, they were not 
significantly different from that at 0.0 μM of hyperforin treatment. 
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Figure 3.27 Chemiluminescent detections of CNPase and β-actin in NS/PCs after 48 
h of differentiation with hyperforin treatment 
CNPase expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and *p < 
0.05, **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
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Figure 3.28 Chemiluminescent detections of CNPase and β-actin in NS/PCs after 96 
h of differentiation with hyperforin treatment 
CNPase expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin and *p < 
0.05 (Mean ± SEM, n=5). HF: Hyperforin.  
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le 3.3). 
3.3.2.3 Hyperforin Increased Expressions of Olig2 but not Ratios of Olig2-positive 
Cells in Differentiating NS/PCs  
Olig2 expressions were detectable by immunocytochemical staining in NS/PCs after 24 
to 96 h of differentiation (Figure 3.29). Hyperforin did not change the ratios of Olig2-
positive cells in differentiating NS/PCs at concentrations between 0.0 μM and 2.5 μM for 
24 h (Figure 3.31, Table 3.2 and Figure 3.32) and 96 h (Figure 3.33, Table 3.3 
and Figure 3.34) as determined by immunocytochemical staining. The ratio of Olig2-
positive cells in the differentiating NS/PCs was approximately 30% with different 
concentrations of hyperforin treatment for 24 h (Table 3.2) and were approximately 40% 
for 96 h (Tab
Hyperforin significantly increased the expression of Olig2 at 2.5 μM (207.3 ± 21.9% of 
the value at 0.0 μM) for 48 h (Figure 3.36). Hyperforin also significantly increased 
expressions of Olig2 at 0.3125 μM (173.2 ± 20.0% of the value at 0.0 μM), 0.625 μM 
(187.2 ± 5.8% of the value at 0.0 μM) and 1.25 μM (170.6 ± 15.5% of the value at 0.0 
μM) for 96 h (Figure 3.37). Hyperforin did not change expressions of Olig2 at 
concentrations between 0.0 μM and 2.5 μM for 24 h (Figure 3.35). The colocalization of 
Olig2 and MBP after 96 h of differentiation indicated that Olig2 was expressed during the 
maturation of oligodendrocytes (Figure 3.30). Hyperforin increased expressions of Olig2, 
CNPase and MBP to high levels at concentrations between 0.3125 μM and 1.25 μM for 
96 h. Hyperforin at 0.625μM simultaneously increased expressions of all three 
oligodendrocyte development-related proteins (Figure 3.38). This suggested that more 
mature oligodendrocytes expressed more Olig2. Hyperforin also simultaneously 
increased the expression of Olig2 and CNPase, the reduction of MTT and the intracellular 
ATP level at 2.5 μM for 48 h (Figure 3.36, Figure 3.27, Figure 3.18 and Figure 3.20).   
  
 
 
Figure 3.29 Fluorescent microphotographs of differentiating NS/PCs expressing 
Olig2 after 96 h of differentiation  
The scale bar represents 50 µm. 
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Figure 3.30 Fluorescent microphotographs of differentiating NS/PCs expressing 
Olig2 and MBP after 96 h of differentiation  
The scale bar represents 50 µm. 
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 Figure 3.31 Fluorescent microphotographs of differentiating NS/PCs expressing 
Olig2 after 24 h of differentiation with hyperforin treatment  
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 24 h. NS/PCs were 
stained with Hoechst 33342 (blue) and Olig2 (Green). HF: Hyperforin. The scale bar represents 500 µm. 
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Table 3.2 Ratios of Olig2-positive cells to total NS/PCs after 24 h of hyperforin 
treatment 
Experiment HF0.0µM HF0.15625µM HF0.3125µM HF0.625µM HF1.25µM HF2.5µM 
1 32.2% 37.2% 38.8% 38.1% 42.6% 36.4% 
2 27.7% 33.9% 34.3% 34.2% 31.2% 33.9% 
3 30.8% 41.0% 37.6% 45.6% 41.3% 44.0% 
4 30.7% 34.4% 37.0% 33.1% 32.9% 35.3% 
Mean ± SEM 30.3% ±1.0% 36.6% ±1.6% 37.0% ±1.0% 37.8% ±2.8% 37.0% ±2.9% 37.4% ±2.3% 
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 24 h. All groups were 
compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: hyperforin. 
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Figure 3.32 Ratios of Olig2-positive cells to total NS/PCs after 24 h of differentiation 
with hyperforin treatment  
Ratios of Olig2-positive cells were calculated after treatment with hyperforin at escalating doses from 0.0 
μM to 2.5 μM for 24 h. All groups were compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: 
Hyperforin. 
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 Figure 3.33 Fluorescent microphotographs of differentiating NS/PCs expressing 
Olig2 after 96 h of differentiation with hyperforin treatment  
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. NS/PCs were 
stained with Hoechst 33342 (blue) and Olig2 (Green). HF: Hyperforin. The scale bar represents 500 µm.  
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Table 3.3 Ratios of Olig2-positive cells to total NS/PCs after 96 h of hyperforin 
treatment 
Experiment HF0.0 µM HF0.15625µM HF0.3125µM HF0.625µM HF1.25µM HF2.5µM 
1 43.7% 41.5% 42.2% 46.8% 45.6% 39.1% 
2 44.1% 41.3% 39.2% 40.8% 42.1% 36.2% 
3 41.0% 37.3% 40.4% 37.6% 36.6% 35.5% 
4 30.4% 37.5% 32.3% 40.1% 36.9% 35.0% 
Mean ± SEM 39.8% ±3.2% 39.4% ±1.2% 38.5% ±2.2% 41.3% ±2.0% 40.3% ±2.2% 36.4% ±0.9% 
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. All groups were 
compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: hyperforin. 
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Figure 3.34 Ratios of Olig2-positive cells to total NS/PCs after 96 h of differentiation 
with hyperforin treatment  
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Ratios of Olig2-positive cells were calculated after treatment with hyperforin at escalating doses from 0.0 
μM to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: 
Hyperforin. 
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Figure 3.35 Chemiluminescent detections of Olig2 and β-actin in NS/PCs after 24 h 
of differentiation with hyperforin treatment  
Olig2 expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 24 h. All groups were compared to 0.0 μM of hyperforin (Mean ± 
SEM, n=4). HF: Hyperforin.  
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Figure 3.36 Chemiluminescent detections of Olig2 and β-actin in NS/PCs after 48 h 
of differentiation with hyperforin treatment 
Olig2 expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 48 h. All groups were compared to 0.0 μM of hyperforin and *p < 
0.05 (Mean ± SEM, n=4). HF: Hyperforin. 
87 
 
 HF0.0 HF0.15625 HF0.3125 HF0.625 HF1.25 HF2.5
0
40
80
120
160
200
240
280
**
**
Hyperforin (μM)
R
el
at
iv
e 
O
lig
2 
ex
pr
es
si
on
 (%
)  96h
 
Figure 3.37 Chemiluminescent detections of Olig2 and β-actin in NS/PCs after 96 h 
of differentiation with hyperforin treatment  
Olig2 expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin and *p < 
0.05, **p < 0.01 (Mean ± SEM, n=5). HF: Hyperforin. 
 
88 
 
  
 CNPase
0
40
80
120
160
200
240  Olig2
##
$
****
Hyperforin (μM)
R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
 (%
)
HF2.5HF1.25HF0.625HF0.3125HF0.15625
 MBP
HF0.0
$
##
 
Figure 3.38 Expressions of Olig2, CNPase and MBP in NS/PCs after 96 h of 
hyperforin treatment  
Protein expression levels expressed as a percentage of the level at HF 0.0 μM after treatment with 
hyperforin at escalating doses from 0.0 to 2.5 μM for 96 h. In each protein expression study, all groups 
were compared to 0.0 μM of hyperforin. In Olig2 expression, *p < 0.05, **p < 0.01 (Mean ± SEM, n=5); in 
CNPase expression, $p < 0.05 (Mean ± SEM, n=5); in MBP expression, ##p < 0.01 (Mean ± SEM, n=5). HF: 
Hyperforin. 
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3.3.3 Hyperforin did not Change Ratios of Astrocytes and Neurons and 
the Expression of GFAP in Differentiating NS/PCs 
The ratios of astrocyte and neurons in differentiating NS/PCs were determined by 
immunocytochemical staining using GFAP (Figure 3.39) and β-III tubulin (Figure 3.43). 
Hyperforin did not change ratios of either GFAP-positive cells (Figure 3.40, Table 3.4 
and Figure 3.41) or β-III tubulin-positive cells (Figure 3.44, Table 3.5 and Figure 3.45) 
in differentiating NS/PCs at concentrations between 0.0 μM and 2.5 μM for 96 h. The 
ratios of GFAP-positive cells were approximately 30% (Table 3.4) after 96 h of 
differentiation. The ratios of β-III tubulin-positive cells were approximately 10% (Table 
3.5) after 96 h of differentiation. Hyperforin did not change the expression of GFAP at 
concentrations between 0.0 μM and 2.5 μM for 96 h as determined by Western blot 
(Figure 3.42).  
 
  
 
 
Figure 3.39 Fluorescent microphotographs of differentiating NS/PCs expressing 
GFAP after 96 h of differentiation  
The scale bar represents 50 µm. 
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 Figure 3.40 Fluorescent microphotographs of differentiating NS/PCs expressing 
GFAP after 96 h of differentiation with hyperforin treatment  
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. NS/PCs were 
stained with Hoechst 33342 (blue) and GFAP (Green). HF: Hyperforin. The scale bar represents 500 µm. 
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Table 3.4 Ratios of GFAP-positive cells to total NS/PCs after 96 h of hyperforin 
treatment 
Experiment HF0.0µM HF0.15625µM HF0.3125µM HF0.625µM HF1.25µM HF2.5µM 
1 31.8% 31.4% 29.3% 30.2% 35.0% 33.3% 
2 31.0% 26.0% 29.9% 28.2% 28.0% 28.8% 
3 36.8% 35.0% 34.6% 33.6% 35.6% 35.3% 
4 31.0% 28.6% 29.7% 28.6% 27.5% 32.9% 
Mean ± SEM 32.6% ± 1.4% 30.2% ± 1.9% 30.9% ± 1.2% 30.1% ± 1.2% 31.5% ± 2.2% 32.6% ± 1.4% 
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. All groups were 
compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: hyperforin. 
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Figure 3.41 Ratios of GFAP-positive cells to total NS/PCs after 96 h of 
differentiation with hyperforin treatment  
Ratios of GFAP -positive cells were calculated after treatment with hyperforin at escalating doses from 0.0 
μM to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: 
Hyperforin. 
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Figure 3.42 Chemiluminescent detections of GFAP and β-actin in NS/PCs after 96 h 
of differentiation with hyperforin treatment  
GFAP expression expressed as a percentage of the level at HF 0.0 μM after treatment with hyperforin at 
escalating doses from 0.0 to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin (Mean ± 
SEM, n=5). HF: Hyperforin. 
94 
 
  
 
 
 
Figure 3.43 Fluorescent microphotographs of differentiating NS/PCs expressing β-
III tubulin after 96 h of differentiation  
The scale bar represents 50 µm. 
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 Figure 3.44 Fluorescent microphotographs of differentiating NS/PCs expressing β-
III tubulin after 96 h of differentiation with hyperforin treatment  
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. NS/PCs were 
stained with Hoechst 33342 (blue) and β-III tubulin (Red). HF: Hyperforin. The scale bar represents 500 
µm. 
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Table 3.5 Ratios of β-III tubulin-positive cells to total NS/PCs after 96 h of 
hyperforin treatment 
Experiment CTL HF0.15625µM HF0.3125µM HF0.625µM HF1.25µM HF2.5µM 
1 11.8% 12.4% 9.8% 11.5% 12.0% 10.4% 
2 11.3% 11.2% 9.0% 10.0% 7.9% 10.1% 
3 10.1% 8.6% 11.0% 11.1% 10.3% 10.0% 
Mean ± SEM 11.1% ±0.5% 10.7% ±1.1% 9.9% ±0.6% 10.9% ±0.4% 10.1% ±1.2% 10.2% ±0.1% 
NS/PCs were treated with hyperforin at escalating doses from 0.0 μM to 2.5 μM for 96 h. All groups were 
compared to 0.0 μM of hyperforin (Mean ± SEM, n=4). HF: hyperforin. 
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Figure 3.45 Ratios of β-III tubulin-positive cells to total NS/PCs after 96 h of 
differentiation with hyperforin treatment 
Ratios of β-III tubulin-positive cells were calculated after treatment with hyperforin at escalating doses 
from 0.0 μM to 2.5 μM for 96 h. All groups were compared to 0.0 μM of hyperforin (Mean ± SEM, n=3). 
HF: Hyperforin. 
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4 DISCUSSION 
4.1 Effects of Hyperforin on the Proliferation of CG-4 Cells 
and NS/PCs 
The reduction of MTT or WST-8 is usually proportional to the number of viable cells in 
the exponential growth phase (Berridge et al., 2005). The increased cell viability 
measured by MTT assay or WST-8 assay usually correlates to the increased cell 
proliferation (Mosmann, 1983). Data from MTT assays or WST-8 assays have indicated 
that hyperforin does not increase the proliferation of either CG-4 cells or NS/PCs. We 
have also found that hyperforin inhibits the proliferation of CG-4 cells, but not the 
primary NS/PCs, at relatively higher concentrations. The growth media of these cell 
cultures contain strong mitogens such as bFGF, EGF and other mitogens (Louis et al., 
1992), hyperforin is not likely to increase rates of proliferation of these fast growing CG-
4 cells and NS/PCs. Some studies have reported that hyperforin decreases proliferation of 
several human and rat cell lines at the growth inhibition 50 (GI50) concentrations between 
3 μM and 15 μM (Dona et al., 2004; Schempp et al., 2002), which suggests that 
hyperforin has a strong anticancer effect. The CG-4 is a spontaneous mutant cell line 
from primary culture of O-2A progenitor cells. Its immortal property due to mutation 
probably makes CG-4 more susceptible to the anticancer effect of hyperforin. Therefore, 
higher concentrations of hyperforin may inhibit or decrease the proliferation of CG-4 
cells by inducing cell cycle arrest or apoptosis. This may also explain why concentrations 
of hyperforin that inhibit the proliferation of CG-4 cells are still quite tolerable for 
proliferating primary NS/PCs. This study has also demonstrated that hyperforin can 
accelerate the differentiation of OPCs into mature oligodendrocytes, so hyperforin may 
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induce the proliferating cells to exit from the cell cycle. This effect could be more 
apparent with CG-4 cells than with NS/PCs, because only part of NS/PCs will 
differentiate into OPCs. Finally, the recipes for growth media and developmental stages 
are quite different for these two cell cultures. These differences could cause the different 
distribution or sensitivities of receptors responding to hyperforin treatment. 
4.2 Effects of Hyperforin on Mitochondrial Function and 
Survival of Differentiating CG-4 Cells and NS/PCs 
The results have demonstrated that hyperforin increases the cell viability, intracellular 
ATP levels and mitochondrial membrane potential in differentiating CG-4 cells at 0.25 
μM and 0.5 μM. Hyperforin at 0.25 μM protects differentiating CG-4 cells from 
rotenone-induced ATP depletion. Hyperforin also increases the cell viability and 
intracellular ATP levels in differentiating NS/PCs at 2.5 μM and 5.0 μM; approximately 
40% of differentiating NS/PCs are OPCs in this study. At these concentrations, 
hyperforin increases all mitochondrial function related parameters without increasing the 
viable cell numbers. That means hyperforin increases the mitochondrial function of each 
cell in these culture systems. All these findings suggest that hyperforin promotes 
mitochondrial function and survival of CG-4 cells and OPCs in vitro at these 
concentrations. However, if hyperforin is administered at higher concentrations than 
those optimal concentrations (0.25 μM and 0.5 μM for OPCs; and 2.5 μM and 5.0 μM for 
NS/PCs), it can cause a decrease in the mitochondrial function in these cells.  
4.2.1 Hyperforin Increases Mitochondrial Function of Differentiating 
CG-4 Cells at Lower Concentrations 
We have confirmed that hyperforin increases cell viability, ATP and mitochondrial 
membrane potential by increasing enzyme activities in mitochondrial citric acid cycle and 
oxidative phosphorylation rather than decreasing energy consumption of cells. Previous 
studies have shown that SJW and hyperforin concordantly regulate the expression of 
genes related to increasing glucose metabolism in a human hepatic cell line (Krusekopf 
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and Roots, 2005). SJW has been found to increase the gene expression of pyruvate 
dehydrogenase which is an important enzyme linking carbohydrate substrates from 
glycolysis to the citric acid cycle (Pennington et al., 2009). Our findings directly prove 
that hyperforin, an important extract in SJW, enhances mitochondrial function by 
increasing activities of key enzymes related to energy production. Decreased generation 
of ATP and mitochondrial membrane potential at higher toxic concentrations can be 
explained by the same mechanism. In physiological conditions, about 1–2% of oxygen is 
not completely reduced to water in mitochondria. This oxygen is first reduced to the 
superoxide anion by leaked electrons and then further reduced by superoxide dismutase 
and glutathione peroxidase into water (Sas et al., 2007). The extreme concentrations of 
hyperforin cause over-activated mitochondrial oxidative phosphorylation, which can lead 
to massive accumulation of hydrogen peroxide that is reduced from superoxide anion by 
superoxide dismutase. Excessive hydrogen peroxide that exceeds the ability of 
glutathione peroxidase to remove it will react with transition metal ions to generate 
highly reactive hydroxyl radicals. The consequent oxidative stress can cause damages to 
DNA and proteins in mitochondria because they are more prone to free radical damage 
than cellular DNA and proteins (Van Houten et al., 2006). Damaged mitochondria will 
lose mitochondrial membrane potential, decrease ATP generation, and release cell death 
signals, such as cytochrome c inducing mitochondria-mediated apoptosis (Brookes et al., 
2004). This explains how hyperforin decreased both ATP generations and mitochondrial 
membrane potential at high toxic concentrations. Our finding that hyperforin increases 
mitochondrial enzyme activity can further explain the previous report that the 
proapoptotic effect of hyperforin is associated with mitochondria-mediated apoptosis 
(Schempp et al., 2002). We suggest that hyperforin will contribute to the optimal function 
of mitochondria, if it is administered at ideal concentrations. 
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4.2.2 Hyperforin Protects CG-4 Cells from Rotenone-induced ATP 
Depletion 
Rotenone disrupts the mitochondrial electron-transport chain at complex I and causes 
acute ATP depletion and generation of massive ROS (Drechsel and Patel, 2008). This 
study has demonstrated the protective effect of hyperforin on attenuating rotenone-
induced cytotoxicity in differentiating CG-4 cells. Two properties of hyperforin may 
contribute to its protective effect. First, the antioxidant effects of hyperforin can protect 
CG-4 cells from oxidative stress induced by rotenone. Hyperforin has been found to 
prevent the endothelial cell mediated low-density lipoprotein oxidation in vitro by 
absorbing free radicals through its chain-breaking antioxidant activity (Laggner et al., 
2007). Hyperforin prevents ROS release through inhibiting the activation of immune cells 
in rat brains (Cabrelle et al., 2008). Hyperforin has also prevented the β-amyloid induced 
neurotoxicity to hippocampal neurons in a rodent model by preventing the β-amyloid-
induced ROS and inflammation (Dinamarca et al., 2006). A standard extract of SJW can 
increase the gene expression of antioxidant enzymes on rotenone-exposed rats (Sanchez-
Reus et al., 2007). Hyperforin may protect CG-4 cells from rotenone-induced oxidative 
stress by absorbing free radicals and increasing the efficiency of antioxidant enzymes. 
The antioxidant effect of hyperforin can also prevent the intracellular oxidative stress in 
CG-4 cells and NS/PCs due to increased redox activities induced by hyperforin itself. 
With the balanced generation and removal of free radicals, CG-4 cells and NS/PCs can 
live with increased mitochondrial functions without showing any oxidative stress. 
Secondly, hyperforin may directly increase mitochondrial function by enhancing the 
activity of mitochondrial complex I. Hyperforin can prevent the ATP depletion induced 
by lower concentration of rotenone, but not by higher concentration of rotenone. This 
suggests that hyperforin and rotenone may compete with each other to bind to the 
mitochondrial complex I. This is the first study to locate the site of action for hyperforin 
increasing mitochondrial function. Future studies should investigate the dose-response 
relationship between hyperforin and the activity of mitochondrial complex I and confirm 
these findings. 
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4.2.3 Hyperforin Increases Mitochondrial Function of CG-4 Cells and 
NS/PCs at Different Dose Ranges 
Hyperforin causes similar patterns of change in mitochondrial function in CG-4 cells and 
NS/PCs, but the effective dose ranges of hyperforin are different. Concentrations of 
hyperforin that either increase or decrease mitochondrial functions in CG-4 cells are 
lower than those in NS/PCs. There are two possible reasons for these differences. The 
first reason could be the differences between the cell line and primary culture. CG-4 as a 
cell line is more susceptible to hyperforin-induced mitochondria-mediated apoptosis at 
relatively higher concentrations. This reason could be also the cause of dose-related 
differences in the proliferation study. The second reason could be the differences between 
single-type cell cultures and mixed cell cultures. During the process of differentiation, 
most CG-4 cells become oligodendrocytes, but NS/PCs are able to differentiate into 
astrocytes, neurons, oligodendrocytes or even other types of neural cells (Reynolds et al., 
1992). The ratios of astrocytes, neurons and oligodendrocytes differentiated from NS/PCs 
are approximately 33: 11: 40 respectively in this study. The biological markers used in 
immunocytochemical staining may not identify other types of neural cells (Gritti et al., 
1996). The presence of astrocytes and neurons could possibly reduce the distribution of 
hyperforin in oligodendrocytes, because both astrocytes and neurons can consume some 
hyperforin for inhibiting neurotransmitter uptake and stimulating cellular receptors in 
them (Neary et al., 2001). The neurotrophic support and interactions of different cell 
types could also contribute to the increased tolerability to higher concentrations of 
hyperforin in differentiating NS/PCs. In differentiating NS/PCs, OPCs only make up 40% 
of the total cells. Therefore, if they cause significant changes (25% of increase) in the 
whole culture system, they may need to reach a higher level of mitochondrial function. In 
other words, higher tolerable concentrations of hyperforin are needed to cause similar 
increases of mitochondrial function in differentiating NS/PCs. In this study, different 
concentrations of hyperforin cause approximately 25% of increases of the cell viability 
and ATP levels in two cell cultures. A future study investigating pure primary OPC 
culture will help us to understand the dose difference, because primary OPC cultures 
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have better tolerability to higher concentrations of hyperforin and less interference from 
other cells compared to CG-4 and NS/PC cultures. 
4.3 Effects of Hyperforin on Development of Oligodendrocytes  
NS/PCs show several advantages in the study of oligodendrocyte development. First, 
OPCs derived from primary embryonic NS/PCs more closely represent the OPCs in 
animal brains. The effects of hyperforin on the development of oligodendrocytes found in 
this model will provide a more reliable outcome of hyperforin treatment in animal studies. 
Second, we can also use this model to determine whether hyperforin has effects on the 
fate decision of NS/PCs. This model may answer whether hyperforin can induce more 
generations of OPCs from differentiating NS/PCs, which can not be evaluated in CG-4 
model. Third, there are some differences between the CG-4 cell line and primary OPCs in 
the study of oligodendrocyte development. CG-4 can provide unlimited numbers of 
oligodendrocyte-like cells. However, unlike the primary O-2A progenitor, CG-4 has no 
real physiological counterpart. During the differentiation into mature oligodendrocytes, 
CG-4 cells express lesser ganglioside GM3, a component of the cell plasma membrane 
involved in cell signal transduction events. CG-4 cells express less myelin associated 
glycoprotein (MAG) and galactocerebroside (GalC) which are important proteins in 
myelin (Bichenkov and Ellingson, 1999; Yim et al., 1995). Only approximately 50% of 
the differentiated CG-4 cells express MBP as determined by immunocytochemical 
staining (Louis et al., 1992). These data suggest that CG-4 may have a lesser degree of 
differentiation than primary O-2A progenitors. In one study, they identified the roles of 
protein kinase C (PKC) pathway and extracellular signal-regulated kinase (ERK) 
pathway in the differentiation and maturation of oligodendrocytes and found differences 
with CG-4 and primary O-2A progenitors (Stariha and Kim, 2001). Other than these 
reported differences, the CG-4 cell line is a valuable model to study oligodendrocyte 
biology. 
Olig2 is essential for oligodendrocyte formation, but Olig2 is also transiently expressed 
in astrocyte progenitor cells (Cai et al., 2007). Some study suggests that Olig2 
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progressively disappears from the nucleus and is sometimes detected in the cytoplasm, 
when NS/PCs begin to differentiate into GFAP-positive astrocytes (Fukuda et al., 2004). 
In the adult brain, the translocation of Olig2 into the cytoplasm is found in the process of 
astroglial activation during brain injury and inflammation (Cassiani-Ingoni et al., 2006; 
Magnus et al., 2007). All these suggest that the downregulated Olig2 expression and its 
translocation into cytoplasma are associated with the maturation and activation of 
astrocytes. In our study, the Olig2-positive staining in the nuclei after 96 h of 
differentiation was used to count the ratio of oligodendrocyte lineage cells to the total 
NS/PCs, and the Olig2 expression was be used to evaluate the maturation of 
oligodendrocytes, because interference from mature astrocytes on the Olig2 expression 
was very limited after 96 h of differentiation. Our previous unpublished data in animal 
study also suggest that the overlapping of double staining with Olig2 and GFAP is hardly 
found in adult animal brains. Olig2 can also be expressed by the progenitor cells of 
peripheral motor neurons in the murine spinal cord (Lu et al., 2002). However, we use the 
NS/PCs from the cortex which are not likely to develop into peripheral motor neurons in 
this culture system. The percentages of oligodendrocyte lineage cells remained constant 
at approximately 40% in the control condition and in different concentrations of 
hyperforin treatment as determined by staining the nuclei with Olig2. The percentages of 
astrocytes lineage and neuron also remained constant at approximately 30% and 10% 
respectively in the control condition and in different concentrations of hyperforin 
treatment as determined by staining of GFAP and β-III tubulin. Data from MBP staining 
have shown that more MBP-positive cells are detectable in the differentiating NS/PCs 
after being treated with 0.625 μM and 1.25 μM of hyperforin for 96 h. Data from Western 
Blot have shown that hyperforin increases expressions of MBP and CNPase, and Olig2 at 
concentrations of 0.625 μM and 1.25 μM for 96 h. These results indicate that hyperforin 
accelerates the maturation process of oligodendrocytes without affecting the fate decision 
of NS/PCs at concentrations of 0.625 μM and 1.25 μM after 96 h of treatment.  
The patterns of expressions of Olig2, CNPase and MBP are almost the same after 96 h of 
hyperforin treatment at the dose range between 0.0 μM and 2.5 μM. This indicates that 
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the increased expression of Olig2 in NS/PCs is associated with the increased 
differentiation and maturation of oligodendrocytes. Animal studies have shown that 
Olig2 is strongly and continuously expressed in oligodendrocytes in the developing and 
adult CNS (Lu et al., 2000). Olig2 overexpression promotes the differentiation of NS/PCs 
into mature oligodendrocytes in vitro (Copray et al., 2006). However, the early increases 
of Olig2 at 24 h and 48 h are not significant at concentrations of 0.625 μM and 1.25 μM, 
so the increased expression of Olig2 could be the result of accelerated maturation of 
oligodendrocytes. Hyperforin may affect other differentiation-related transcription factors 
such as NK2 homeobox 2 (Nkx2.2), because Olig2 accompanying with other 
transcription factors including Nkx2.2 collaboratively regulate the differentiation of 
oligodendrocytes from neural progenitor cells (Zhou et al., 2001). Recent studies have 
also shown that expression of Olig2 can induce early oligodendrocyte precursor markers 
such as PDGF receptor α, but not later markers such as MBP (Zhou et al., 2001). Nkx2.2 
expression appears to be necessary for proliferation and migration of OPCs, and it is also 
crucial for the expression of MBP in mature oligodendrocytes (Qi et al., 2001; Xu et al., 
2000). Nkx2.2 expression is downregulated with oligodendrocyte differentiation, which 
is different from the expression of Olig2 (Xu et al., 2000). A future study should evaluate 
the effect of hyperforin on Nkx2.2 or other important factors on the regulation of 
oligodendrocyte development. 
4.3.1 The Relationship between Increased Mitochondrial Function and 
Accelerated Development of Oligodendrocytes  
We have demonstrated that hyperforin increases both mitochondrial function and 
development of OPCs into mature oligodendrocytes. It was observed that the pattern of 
early increased mitochondrial function as determined by the MTT assay and the ATP 
assay resembled the patterns of expressions of Olig2 and CNPase at the early stage of 
oligodendrocyte development. These parameters were significantly increased after 2.5 
μM of hyperforin treatment for 48 h. There may be some correlation between the 
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increased mitochondrial function and accelerated differentiation and maturation of 
oligodendrocytes.  
Increased mitochondrial function will provide beneficial support for the differentiation 
and maturation of OPCs, because of the high energy consumption in developing 
oligodendrocytes during the process of myelination (Connor and Menzies, 1996; Pleasure 
et al., 1977). Furthermore, recent studies have shown that intracellular redox status play 
an important role in modulating the balance between self-renewal proliferation and 
differentiation in dividing O-2A progenitor cells (Noble et al., 2003). Signaling 
molecules that promote O-2A progenitor cell differentiation into oligodendrocytes cause 
greater intracellular oxidative turnover, whereas signaling molecules that promote self-
renewal cause more reduced intracellular states. Pharmacological agents that antagonize 
the redox effects of these molecules also antagonize their effects on self-renewal and 
differentiation (Smith et al., 2000). We have found that hyperforin increases the 
mitochondrial function by increasing the oxidative phosphorylation, and this effect could 
be due to the promotion of OPCs differentiation into oligodendrocytes.  
It is also possible that hyperforin-induced maturation of oligodendrocytes requires cells 
to increase mitochondrial function and generate more ATP to meet the demand of energy 
consumption for faster synthesis of myelin. The latest study of myelin function discloses 
that isolated myelin vesicles are able to consume oxygen and produce ATP through the 
operation of a proton gradient across their membranes. It also shows the colocalization of 
the ATP synthase and MBP on isolated myelin vesicles and axon nerves (Ravera et al., 
2009). This evidence suggests that myelin sheath could also be the site of oxygen 
absorption and aerobic metabolism for the axons, so the increased myelin production 
could also be a resource for increased energy production in myelinating oligodendrocytes.  
It is also possible that both processes are controlled by a common pathway that can be 
affected by hyperforin, so they will increase together with hyperforin treatment. A 
genomic study reports that the gene of peroxisome proliferator activated receptor-γ 
(PPAR-γ) is significantly unregulated by treatment of SJW and hyperforin (Houseknecht 
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et al., 2002; Krusekopf and Roots, 2005). PPAR-γ has been found in adult and 
developing brains and spinal cords (Heneka and Landreth, 2007). PPAR-γ regulates the 
expression of several genes related to lipid uptake and synthesis (Walczak and Tontonoz, 
2002) as well as the enhancement of cellular glucose uptake (Gervois et al., 2007). 
Oligodendrocytes are major lipid producing cells with high energy consumption in the 
CNS, so PPAR-γ is likely to affect the maturation and function of oligodendrocytes by 
regulating the lipid synthesis and energy supply during the myelination. PPAR-γ is also 
involved in the proliferation and differentiation of neural stem cells (Wada et al., 2006). 
PPAR-γ agonists are found to promote the differentiation of cultured spinal cord 
oligodendrocytes by the increasing percentage of cells expressing MBP (Roth et al., 
2003). In another study, PPAR-γ agonists not only promote the differentiation of primary 
rat OPCs but also enhance their antioxidant defenses by increasing the levels of catalase 
and superoxide dismutase (Bernardo et al., 2009; Sim et al., 2008). A novel 
thiadiazolidinone, a PPAR-γ agonist, has shown antidepressant effects in the forced 
swimming test, and this effect is inhibited by PPAR-γ antagonists (Rosa et al., 2008). 
Hyperforin may increase the mitochondrial energy metabolism and development of OPCs 
at the same time by stimulating expression of PPAR-γ, and these effects on 
oligodendrocytes may eventually contribute to the antidepressant effect of hyperforin. 
4.4 Implications of Antidepressant Treatment on 
Mitochondrial Function and Development of 
Oligodendrocytes in MDD 
This study has demonstrated that hyperforin promotes mitochondrial function and 
development of oligodendrocytes in vitro. Many studies have already shown that the 
clinical symptoms and pathological changes in MDD are related to the mitochondrial 
malfunction and loss of oligodendrocytes. Antidepressant treatment including 
antidepressants and ECT have shown a tendency to increase both mitochondrial function 
and available functioning oligodendrocytes in the brain. It is possible that these are 
common effects shared by different antidepressant treatment.  
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4.4.1 Antidepressant Treatment May Prevent the Mitochondrial 
Dysfunction-Related Oligodendrocyte Malfunction in MDD 
Functional neuroimaging studies with positron emission tomography (PET) have found 
decreased cerebral blood flow and glucose metabolism in the prefrontal cortex, the basal 
ganglia and the hippocampus in brains of MDD patients (Buchsbaum et al., 1986; 
Drevets et al., 1997). Blood flow and glucose metabolism were normalized when patients 
recovered from MDD (Videbech, 2000). In a study measuring high-energy phosphates in 
MDD using 31phosphorus magnetic resonance spectroscopy (31P-MRS), the ATP levels 
were found to be lower in patients than in normal controls (Moore et al., 1997). Creatine 
phosphate is a high-energy phosphate that can be readily transferred to ATP by the 
enzyme creatine kinase. The levels of creatine phosphate were lower in the severe 
depression group compared to the mild depression group. This study suggests that the 
deficiency of the energy metabolism may be related to the severity of depression (Kato et 
al., 1998). Genetic studies have shown that decreased mitochondrial DNA transcription 
and mitochondrial diseases are highly correlated to MDD (Fattal et al., 2006; Shao et al., 
2008). In chronic stress animal models of depression, the activities of complex I, II, III 
and IV in mitochondrial electron-transport chain were inhibited after 21 days and 40 days 
of stress (Madrigal et al., 2001; Rezin et al., 2008). The complexes I, III and IV were 
only inhibited in the cerebral cortex and cerebellum (Rezin et al., 2008), where structural 
abnormalities have also been found in patients with mood disorders (Konarski et al., 
2008). These studies suggest that mitochondrial dysfunction is closely related to the 
severities of symptoms and structural abnormalities found in patients with MDD. 
Furthermore, both mitochondrial dysfunction and oligodendrocyte loss or malfunctions 
are found around the prefrontal cortex and the limbic system in the brains of patients with 
MDD (Buchsbaum et al., 1986; Hamidi et al., 2004; Honer et al., 1999). In these areas, 
decreased mitochondrial function may directly affect the function of oligodendrocytes 
and the myelination process, because reduced energy supply may not be enough for 
109 
 
oligodendrocytes to maintain and generate a large amount of myelin (Connor and 
Menzies, 1996; Pleasure et al., 1977). Impaired oligodendrocytes will affect the 
information transduction in those brain areas; which are important for emotion and social 
behavior (Phelps and LeDoux, 2005).  
In this study, hyperforin specifically increases the mitochondrial function in 
differentiating CG-4 cells and protects these cells from neurotoxin-induced mitochondrial 
malfunction. Several studies have shown that SJW and hyperforin can upregulate gene 
expressions related to increasing glycolysis and cellular glucose uptake in the 
hippocampus and other tissue (Krusekopf and Roots, 2005; Pennington et al., 2009). A 
recent 31P-MRS study suggests that agents with the ability to increase brain ATP levels 
may show antidepressant effect (Moretti et al., 2003). A variety of antidepressants 
including imipramine, amitriptyline and clomipramine increase the ATP generation of 
astrocytes in vitro and this may affect the differentiation of astrocytes (Trzeciak et al., 
1995). Fluoxetine has been found to enhance glycogenolysis in cultured astrocytes and 
could thus improve energy supply in rodent brains (Kong et al., 2002; Zhang et al., 1993). 
ECT treatment has been found to increase activities of mitochondrial complexes II and 
IV in brains of rats (Burigo et al., 2006). Another study indicates that the antidepressant 
effect of thyroid hormone augmentation of SSRIs is correlated with significant increases 
in ATP levels and other bioenergetics in the brains of patients with MDD (Iosifescu et al., 
2008). These studies suggest that antidepressants may increase energy metabolism by 
increasing mitochondrial function in the brain. This effect may attenuate the 
oligodendrocyte malfunction that would be induced by an energy deficiency in the brains 
of patients with MDD. 
4.4.2 Antidepressant Treatment May Increase Functioning of 
Oligodendrocytes in MDD 
Myelination is not complete after birth, and it continues into the fifth decade of human 
life (Bartzokis et al., 2001; Benes et al., 1994). The continuous myelination allows 
oligodendrocytes to keep modifying the synaptic connections. It is believed that this 
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ongoing modification helps the brain to achieve the optimal information processing 
according to life experiences, such as increased social interaction and cognitive 
stimulation (Fields, 2005). The molecular mechanism of remodeling synaptic function 
has recently been discovered. Oligodendrocytes are able to sense the impulse activity in 
axons via their ion channels and membrane receptors and dynamically change 
myelination patterns for optimal function according to the impulse (Stevens et al., 1998). 
Furthermore, communication through synaptic junctions between axon terminals and the 
processes of OPCs also help newly generated OPCs to migrate and form myelin at 
optimal locations (Bergles et al., 2000). Oligodendrocytes are more actively involved in 
the dynamic control of the output of neuronal communication than previously believed 
(Yamazaki et al., 2009). To fulfill the dynamic control and remodeling of the neuronal 
conductions, the brain needs to maintain sufficient levels of functioning oligodendrocytes 
and newly generated OPCs. After CNS development is complete, some OPCs remain in 
the adult brain and spinal cord. These OPCs can further differentiate into mature 
oligodendrocytes (Noble et al., 1992). The genesis of NG2-positive cells that can 
differentiate into OPCs is also very common throughout the brain (Kornack and Rakic, 
2001). A gene study of postmortem brain tissues of patients with MDD has revealed that 
expressions of 17 genes related to myelination are decreased. Eight of these 17 genes 
encode the structural components of myelin including CNPase and MAG. Several 
oligodendrocyte development genes including Olig2 are also decreased in MDD (Aston 
et al., 2005). The decreases of oligodendrocyte density, myelin staining and MBP 
expressions have also been found in the brains of patients with MDD (Hamidi et al., 2004; 
Honer et al., 1999; Regenold et al., 2007). Both genesis and myelination of 
oligodendrocytes are impaired in MDD.   
This study has demonstrated that hyperforin prevents the loss of OPCs and accelerates 
the development of OPCs into mature oligodendrocytes by increasing expressions of 
Olig2, CNPase and MBP. This suggests that hyperforin as an extract in SJW can reverse 
the pathophysiological changes in oligodendrocytes in the brains of patients with MDD, 
which could be a possible mechanism of action for its clinical efficacy. However, 
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hyperforin did not induce the proliferation of OPCs and NS/PCs in this study, so it can 
not show more effects by enlarging these pools of OPCs. Other antidepressant treatment 
has been found to have effects on promoting genesis of oligodendrocytes. Fluoxetine and 
imipramine prevent the loss of neural stem cells in a chronic stress animal model (Hitoshi 
et al., 2007). Fluoxetine and ECT can induce the genesis of bipotential glial progenitors 
and OPCs in animal brains (Hitoshi et al., 2007; Wennstrom et al., 2004). Fluoxetine has 
also shown an ability to promote the development of oligodendrocytes by increasing the 
expressions of insulin-like growth factor I (IGF-I) and its receptor in rat brains 
(Grunbaum-Novak et al., 2008). These findings suggest a possible outcome of 
antidepressant treatment is to increase the available functioning oligodendrocytes in the 
brains of patients with MDD by increasing the genesis or development of OPCs.  
Most treatment for depression, including hyperforin in SJW, synthetic antidepressants 
and ECT increases the synaptic serotonin or norepinephrine levels (Berton and Nestler, 
2006; Muller et al., 1998; Taylor, 2007). By increasing the monoaminergic 
neurotransmission, chronic antidepressant treatment increases cAMP and upregulates the 
function and expression of the transcription factor CREB, which can increase the 
expressions of neurotrophic factors (Duman, 2002). Expression of IGF-I could also be 
increased by modulating cAMP levels (Palacios et al., 2005). A recent study has shown 
that chronic treatment of fluoxetine increases the levels of both IGF-1 mRNA and IGF-I 
receptors in the frontal cortex but not the hippocampus in rat brains (Grunbaum-Novak et 
al., 2008). Furthermore, intracerebroventricular administration of IGF-I has shown 
antidepressant-like behavioral effects with increased serotonin transmissions in rodent 
models (Hoshaw et al., 2008). CREB is also highly expressed in oligodendrocytes (Sato-
Bigbee and Yu, 1993; Sato-Bigbee et al., 1994). Studies have shown that IGF-I can 
induce multipotent adult neural progenitor cells to become oligodendrocytes (Hsieh et al., 
2004). IGF-I also stimulates oligodendrocyte development and myelination in vitro 
(Mozell and McMorris, 1991) and in mouse brains (Zeger et al., 2007). Through 
regulating CREB and expressions of IGF-I and its receptors, chronic antidepressant 
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treatment may promote the genesis and development of oligodendrocytes from neural 
progenitor cells in the brain. 
This study and previous studies suggest that increasing the genesis and development of 
oligodendrocytes could be a mechanism of action for chronic antidepressant treatment. 
This mechanism would explain some of the pathological changes in depression and the 
effects of chronic antidepressant treatment on oligodendrocytes. It also necessary to 
examine whether the antidepressants that induce both genesis and development of 
oligodendrocytes have a better efficacy than antidepressants that have a single effect on 
oligodendrocytes. 
4.4.3 The Mechanism of Action for Chronic Antidepressant Treatment 
May be Mediated through Oligodendrocytes 
This study and previous studies suggest that antidepressant treatment may promote 
mitochondrial function and development of oligodendrocytes. Antidepressants may 
increase functioning oligodendrocytes, which may compensate for the loss and 
malfunction of oligodendrocytes in the brains of patients with MDD. If this is a possible 
mechanism of action for chronic antidepressant treatment, drug development could focus 
on oligodendrocytes as a therapeutic target. Recent studies have reported that quetiapine, 
an atypical antipsychotic approved for depression treatment, promotes both the 
proliferation of the NS/PCs and maturation of oligodendrocytes in cell cultures as well as 
in a demyelination animal model (Xiao et al., 2008; Zhang et al., 2008). Chronic 
administration of quetiapine has also shown efficacy as an effective monotherapy for 
MDD in clinical trials (Cutler et al., 2009; Weisler et al., 2009). Quetiapine shows a 
moderate effect on serotonin receptors, which could contribute to the efficacy; but the 
effect is different from that of synthetic antidepressants (Yatham et al., 2005). However, 
chronic treatment of quetiapine is still needed to reduce depressive symptoms in clinical 
trials. The close relationship between oligodendrocyte function and the chronic treatment 
with quetiapine suggests that the antidepressant effect may also be mediated through 
enhancing oligodendrocyte function.  
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4.5 Future Studies Are Needed to Decipher the Underlying 
Mechanism of Hyperforin in Promoting Oligodendrocyte 
Function 
We have demonstrated that hyperforin promotes both mitochondrial function and 
development of oligodendrocytes at optimal concentrations. Hyperforin can directly 
increase the intracellular the cell viability and enzyme activity of complex I on the 
mitochondrial electron-transport chain. It is also possible that hyperforin works on other 
targets that can induce increased energy metabolism and differentiation of 
oligodendrocytes. We think PPAR-γ is a candidate to examine. The possible increase of 
PPAR-γ expression will also explain the anti-inflammatory effect of hyperforin in the 
CNS, because PPAR-γ is also involved in the immunoresponse and cytokine release 
(Heneka and Landreth, 2007).  
Neural stem cells differentiate into different cell types at the same time in the human 
brain, so the differentiating NS/PC model closely resembles the differentiating neural 
stem cells in human brains. We have demonstrated that hyperforin promotes the 
development of oligodendrocytes without affecting the ratios of different cell lineages. 
However, astrocytes, neurons or other neural cells may still contribute to the development 
of oligodendrocytes. Astrocytes can release a specific cytokine into its surrounding 
environment, which induces the differentiation and myelination of oligodendrocytes 
(Ishibashi et al., 2006). The primary culture of OPCs will be very useful in further 
identifying the mechanism by which hyperforin promotes oligodendrocyte development.  
Hyperforin has shown efficacy in reversing depressive-like behavior in animal models 
(Cervo et al., 2002; Gambarana et al., 2001), so the examination of oligodendrocyte 
changes in the brains of control animals and hyperforin-treated animals will provide more 
information on the relationship among reduced symptoms, oligodendrocyte changes and 
hyperforin treatment. Although several studies have shown antidepressant treatment can 
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induce genesis of neural stem cells and promote their survival (Hitoshi et al., 2007; 
Wennstrom et al., 2004), this is the first study to provide direct evidence that an 
antidepressant compound promotes the development of OPCs from neural stem cells. 
Whether other synthetic antidepressants share the same effects as hyperforin on 
oligodendrocytes needs to be confirmed by future studies. 
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5 CONCLUSION 
Hyperforin increases mitochondrial function and prevents mitochondrial toxin-induced 
cytotoxicity in differentiating oligodendrocytes. Hyperforin also promotes the 
development of differentiating oligodendrocytes rather than increasing the proliferation 
of OPCs and NS/PCs. These findings suggest that hyperforin may increase the available 
functioning oligodendrocytes by promoting the mitochondrial function, survival and 
development of oligodendrocytes. Our findings in conjunction with past studies suggest 
that the mechanism of action of chronic antidepressant treatment may be increasing the 
function of oligodendrocytes in the brains of patients with MDD. Future studies should 
explore the detailed mechanisms of hyperforin and other antidepressants on promoting 
mitochondrial function and development of oligodendrocytes in cell cultures and animal 
models.  
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